

# Nintedanib for Systemic Sclerosisâ€™Associated Interst

New England Journal of Medicine

380, 2518-2528

DOI: [10.1056/nejmoa1903076](https://doi.org/10.1056/nejmoa1903076)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Chronic Lung Allograft Dysfunction: Evolving Concepts and Therapies. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2018, 39, 155-171.	0.8	37
2	Progressive fibrosing interstitial lung disease associated with systemic autoimmune diseases. <i>Clinical Rheumatology</i> , 2019, 38, 2673-2681.	1.0	38
4	The Fibrosis Burden of Systemic Sclerosis. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2019, 200, 1200-1202.	2.5	1
5	Current and Emerging Drug Therapies for Connective Tissue Disease-Interstitial Lung Disease (CTD-ILD). <i>Drugs</i> , 2019, 79, 1511-1528.	4.9	35
6	Pulmonary Manifestations of Systemic Sclerosis and Mixed Connective Tissue Disease. <i>Clinics in Chest Medicine</i> , 2019, 40, 501-518.	0.8	32
8	Potential of nintedanib in treatment of progressive fibrosing interstitial lung diseases. <i>European Respiratory Journal</i> , 2019, 54, 1900161.	3.1	164
9	Progressive fibrosing interstitial lung diseases: current practice in diagnosis and management. <i>Current Medical Research and Opinion</i> , 2019, 35, 2015-2024.	0.9	148
11	Nintedanib for Systemic Sclerosis-Associated Interstitial Lung Disease. <i>New England Journal of Medicine</i> , 2019, 381, 1595-1597.	13.9	12
12	Methotrexate-Associated Pneumonitis and Rheumatoid Arthritis-Interstitial Lung Disease: Current Concepts for the Diagnosis and Treatment. <i>Frontiers in Medicine</i> , 2019, 6, 238.	1.2	73
13	Idiopathic and immune-related pulmonary fibrosis: diagnostic and therapeutic challenges. <i>Clinical and Translational Immunology</i> , 2019, 8, e1086.	1.7	22
14	Gas6/TAM System: A Key Modulator of the Interplay between Inflammation and Fibrosis. <i>International Journal of Molecular Sciences</i> , 2019, 20, 5070.	1.8	59
15	Exosomes in Systemic Sclerosis: Messengers Between Immune, Vascular and Fibrotic Components?. <i>International Journal of Molecular Sciences</i> , 2019, 20, 4337.	1.8	37
18	Systemic sclerosis. <i>British Journal of Hospital Medicine (London, England: 2005)</i> , 2019, 80, 530-536.	0.2	75
19	Nintedanib in Progressive Fibrosing Interstitial Lung Diseases. <i>New England Journal of Medicine</i> , 2019, 381, 1718-1727.	13.9	1,338
20	Current and future perspectives on management of systemic sclerosis-associated interstitial lung disease. <i>Expert Review of Clinical Immunology</i> , 2019, 15, 1009-1017.	1.3	42
21	Systemic sclerosis - multidisciplinary disease: clinical features and treatment. <i>Reumatologia</i> , 2019, 57, 221-233.	0.5	82
22	Treatment of idiopathic pulmonary fibrosis with Nintedanib: an update. <i>Expert Review of Respiratory Medicine</i> , 2019, 13, 1139-1146.	1.0	13
23	Interstitial Pneumonia With Autoimmune Features (IPAF). <i>Frontiers in Medicine</i> , 2019, 6, 209.	1.2	47

#	ARTICLE	IF	CITATIONS
24	Nintedanib slows ILD progression in SSc. <i>Nature Reviews Rheumatology</i> , 2019, 15, 384-384.	3.5	3
25	Proteinase 3 (PR3)-antineutrophil cytoplasmic antibody (ANCA)-associated vasculitic neuropathy in diffuse cutaneous systemic sclerosis: a rare duo. <i>BMJ Case Reports</i> , 2019, 12, e232987.	0.2	3
26	ERS International Congress 2019: highlights from Best Abstract awardees. <i>Breathe</i> , 2019, 15, e143-e149.	0.6	0
27	Treatment of progressive fibrosing interstitial lung diseases: a milestone in the management of interstitial lung diseases. <i>European Respiratory Review</i> , 2019, 28, 190109.	3.0	49
28	Endotypeâ€“phenotyping may predict a treatment response in progressive fibrosing interstitial lung disease. <i>EBioMedicine</i> , 2019, 50, 379-386.	2.7	41
29	Vascularised human skin equivalents as a novel in vitro model of skin fibrosis and platform for testing of antifibrotic drugs. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 1686-1692.	0.5	32
30	Systemic Sclerosis Associated Interstitial Lung Disease: New Directions in Disease Management. <i>Frontiers in Medicine</i> , 2019, 6, 248.	1.2	13
33	Prognostic value of cardiopulmonary exercise testing in patients with systemic sclerosis. <i>BMC Pulmonary Medicine</i> , 2019, 19, 230.	0.8	24
34	The nosology of systemic sclerosis: how lessons from the past offer new challenges in reframing an idiopathic rheumatological disorder. <i>Lancet Rheumatology</i> , The, 2019, 1, e257-e264.	2.2	17
35	Challenges in systemic sclerosis trial design. <i>Seminars in Arthritis and Rheumatism</i> , 2019, 49, S3-S7.	1.6	13
36	&lt;p&gt;Interstitial Lung Disease in Systemic Sclerosis: Focus on Early Detection and Intervention&lt;/p&gt;. <i>Open Access Rheumatology: Research and Reviews</i> , 2019, Volume 11, 283-307.	0.8	23
37	Macrophages and cadherins in fibrosis and systemic sclerosis. <i>Current Opinion in Rheumatology</i> , 2019, 31, 582-588.	2.0	16
38	Detection and classification of systemic sclerosis-related interstitial lung disease: a review. <i>Current Opinion in Rheumatology</i> , 2019, 31, 553-560.	2.0	15
39	Biomarkers in systemic sclerosis. <i>Current Opinion in Rheumatology</i> , 2019, 31, 595-602.	2.0	19
40	18F-AzaFol for Detection of Folate Receptor-Î² Positive Macrophages in Experimental Interstitial Lung Diseaseâ€“A Proof-of-Concept Study. <i>Frontiers in Immunology</i> , 2019, 10, 2724.	2.2	27
42	Systemic sclerosis: Recent insight in clinical management. <i>Joint Bone Spine</i> , 2020, 87, 293-299.	0.8	31
43	Pamrevlumab in idiopathic pulmonary fibrosis. <i>Lancet Respiratory Medicine</i> , the, 2020, 8, 2-3.	5.2	14
44	Interstitial lung disease: perhaps unclassifiable, but not untreatable. <i>Lancet Respiratory Medicine</i> , the, 2020, 8, 126-127.	5.2	2

#	ARTICLE	IF	CITATIONS
45	Pirfenidone in patients with unclassifiable progressive fibrosing interstitial lung disease: a double-blind, randomised, placebo-controlled, phase 2 trial. <i>Lancet Respiratory Medicine</i> , 2020, 8, 147-157.	5.2	410
46	Lung disease related to connective tissue diseases. , 2020, , 265-319.		0
47	A role of antifibrotics in the treatment of Scleroderma-ILD?. <i>Pulmonology</i> , 2020, 26, 1-2.	1.0	5
48	Defining genetic risk factors for scleroderma-associated interstitial lung disease. <i>Clinical Rheumatology</i> , 2020, 39, 1173-1179.	1.0	12
49	Endotyping of progressive fibrotic interstitial lung diseases: It is the final destination that matters and not the journey. <i>EBioMedicine</i> , 2020, 51, 102591.	2.7	3
50	Ongoing challenges in pulmonary fibrosis and insights from the nintedanib clinical programme. <i>Respiratory Research</i> , 2020, 21, 7.	1.4	19
51	Metabolic profiling of tyrosine kinase inhibitor nintedanib using metabolomics. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2020, 180, 113045.	1.4	11
52	Etiology, Risk Factors, and Biomarkers in Systemic Sclerosis with Interstitial Lung Disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2020, 201, 650-660.	2.5	105
53	Characterizing Disease Manifestations and Treatment Patterns Among Adults with Systemic Sclerosis: A Retrospective Analysis of a US Healthcare Claims Population. <i>Rheumatology and Therapy</i> , 2020, 7, 89-99.	1.1	10
55	Rationally-based therapeutic disease modification in systemic sclerosis: Novel strategies. <i>Seminars in Cell and Developmental Biology</i> , 2020, 101, 146-160.	2.3	20
56	Nintedanib: New indication for systemic sclerosis-associated interstitial lung disease. <i>Modern Rheumatology</i> , 2020, 30, 225-231.	0.9	29
57	Natural history of systemic sclerosis-related interstitial lung disease: How to identify a progressive fibrosing phenotype. <i>Journal of Scleroderma and Related Disorders</i> , 2020, 5, 31-40.	1.0	34
58	Evasion of apoptosis by myofibroblasts: a hallmark of fibrotic diseases. <i>Nature Reviews Rheumatology</i> , 2020, 16, 11-31.	3.5	320
60	Skin improvement is a surrogate for favourable changes in other organ systems in early diffuse cutaneous systemic sclerosis. <i>Rheumatology</i> , 2020, 59, 1715-1724.	0.9	14
61	An Open-label Study With Pirfenidone on Chronic Hypersensitivity Pneumonitis. <i>Archivos De Bronconeumologia</i> , 2020, 56, 163-169.	0.4	20
62	Automatic Quantitative Computed Tomography Evaluation of the Lungs in Patients With Systemic Sclerosis Treated With Autologous Stem Cell Transplantation. <i>Journal of Clinical Rheumatology</i> , 2020, 26, S158-S164.	0.5	8
63	Detection, screening, and classification of interstitial lung disease in patients with systemic sclerosis. <i>Current Opinion in Rheumatology</i> , 2020, 32, 497-504.	2.0	15
64	Azathioprine for Connective Tissue Disease-Associated Interstitial Lung Disease: In Search for Evidence-Based Medicine. <i>Respiration</i> , 2020, 99, 930-931.	1.2	0

#	ARTICLE	IF	CITATIONS
65	Interstitial Lung Disease in Patients With Systemic Sclerosis: Toward Personalized-Medicine-Based Prediction and Drug Screening Models of Systemic Sclerosis-Related Interstitial Lung Disease (SSc-ILD). <i>Frontiers in Immunology</i> , 2020, 11, 1990.	2.2	9
66	Automatic Quantification of Interstitial Lung Disease From Chest Computed Tomography in Systemic Sclerosis. <i>Frontiers in Medicine</i> , 2020, 7, 577739.	1.2	5
67	Emerging drugs for the treatment of scleroderma: a review of recent phase 2 and 3 trials. <i>Expert Opinion on Emerging Drugs</i> , 2020, 25, 455-466.	1.0	7
68	Safety and efficacy of abatacept in early diffuse cutaneous systemic sclerosis (ASSET): open-label extension of a phase 2, double-blind randomised trial. <i>Lancet Rheumatology</i> , The, 2020, 2, e743-e753.	2.2	34
69	Correspondence on "Safety and tolerability of nintedanib in patients with systemic sclerosis-associated interstitial lung disease: data from the SENSICIS trial"™. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, e250-e250.	0.5	3
70	The Pulmonary Fibrosis Foundation Patient Registry. Rationale, Design, and Methods. <i>Annals of the American Thoracic Society</i> , 2020, 17, 1620-1628.	1.5	27
71	Australasian interstitial lung disease registry (AILDR): objectives, design and rationale of a bi-national prospective database. <i>BMC Pulmonary Medicine</i> , 2020, 20, 257.	0.8	9
72	Treatment of systemic sclerosis-associated interstitial lung disease: A systematic literature review and meta-analysis. <i>Revista Colombiana De Reumatología (English Edition)</i> , 2020, 27, 146-169.	0.1	0
73	Current immunosuppressive and antifibrotic therapies of systemic sclerosis and emerging therapeutic strategies. <i>Expert Review of Clinical Pharmacology</i> , 2020, 13, 1203-1218.	1.3	4
74	Safety and efficacy of rituximab biosimilar (CT-P10) in systemic sclerosis: an Italian multicentre study. <i>Rheumatology</i> , 2020, 59, 3731-3736.	0.9	21
76	miR-301a Suppression within Fibroblasts Limits the Progression of Fibrosis through the TSC1/mTOR Pathway. <i>Molecular Therapy - Nucleic Acids</i> , 2020, 21, 217-228.	2.3	12
77	Riociguat in systemic sclerosis: a potential for disease modification. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, e116-e116.	0.5	2
78	Azathioprine for Connective Tissue Disease-Associated Interstitial Lung Disease. <i>Respiration</i> , 2020, 99, 628-636.	1.2	12
79	The adoption of nintedanib in systemic sclerosis: the SENSICIS study. <i>Breathe</i> , 2020, 16, 200005.	0.6	5
80	An update on the pharmacotherapeutic options and treatment strategies for systemic sclerosis. <i>Expert Opinion on Pharmacotherapy</i> , 2020, 21, 2041-2056.	0.9	15
81	Serum biomarker CA 15-3 as predictor of response to antifibrotic treatment and survival in idiopathic pulmonary fibrosis. <i>Biomarkers in Medicine</i> , 2020, 14, 997-1007.	0.6	5
82	Drugs that act on the respiratory tract. <i>Side Effects of Drugs Annual</i> , 2020, 42, 171-181.	0.6	1
84	Progressive Fibrosing Interstitial Lung Diseases: Prevalence and Characterization in Two Italian Referral Centers. <i>Respiration</i> , 2020, 99, 838-845.	1.2	35

#	ARTICLE	IF	CITATIONS
85	Immunomodulation in Autoimmune Interstitial Lung Disease. <i>Respiration</i> , 2020, 99, 819-829.	1.2	4
86	Clinical experience with antifibrotics in fibrotic hypersensitivity pneumonitis: a 3-year real-life observational study. <i>ERJ Open Research</i> , 2020, 6, 00152-2020.	1.1	15
87	Rituximab as a rescue treatment added on mycophenolate mofetil background therapy in progressive systemic sclerosis associated interstitial lung disease unresponsive to conventional immunosuppression. <i>Seminars in Arthritis and Rheumatism</i> , 2020, 50, 977-987.	1.6	16
88	Oxygen for interstitial lung diseases. <i>Current Opinion in Pulmonary Medicine</i> , 2020, 26, 464-469.	1.2	7
89	Systemic sclerosis-associated interstitial lung disease. <i>Current Opinion in Pulmonary Medicine</i> , 2020, 26, 487-495.	1.2	3
90	Recent advances in rheumatoid arthritis-associated interstitial lung disease. <i>Current Opinion in Pulmonary Medicine</i> , 2020, 26, 477-486.	1.2	31
91	Progressive fibrosing interstitial lung disease: treatable traits and therapeutic strategies. <i>Current Opinion in Pulmonary Medicine</i> , 2020, 26, 436-442.	1.2	18
92	Safety and tolerability of nintedanib in patients with systemic sclerosis-associated interstitial lung disease: data from the SENSICIS trial. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 1478-1484.	0.5	46
93	Connective Tissue Disease-Related Interstitial Lung Disease: Prevalence, Patterns, Predictors, Prognosis, and Treatment. <i>Lung</i> , 2020, 198, 735-759.	1.4	44
94	Bi-directional communication: Conversations between fibroblasts and immune cells in systemic sclerosis. <i>Journal of Autoimmunity</i> , 2020, 113, 102526.	3.0	29
95	Disentangling inflammatory from fibrotic disease activity by fibroblast activation protein imaging. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 1485-1491.	0.5	111
96	Enrichment Strategy for Systemic Sclerosis Clinical Trials Targeting Skin Fibrosis: A Prospective, Multiethnic Cohort Study. <i>ACR Open Rheumatology</i> , 2020, 2, 496-502.	0.9	6
97	Lung Involvement in Primary Sjögren's Syndrome – An Under-Diagnosed Entity. <i>Frontiers in Medicine</i> , 2020, 7, 332.	1.2	26
98	Pulmonary involvement in systemic sclerosis: exploring cellular, genetic and epigenetic mechanisms. <i>Rheumatology International</i> , 2020, 40, 1555-1569.	1.5	11
99	The need for a holistic approach for SSc-ILD – achievements and ambiguity in a devastating disease. <i>Respiratory Research</i> , 2020, 21, 197.	1.4	33
100	Efficacy, Safety, and Tolerability of Treatments for Systemic Sclerosis-Related Interstitial Lung Disease: A Systematic Review and Network Meta-Analysis. <i>Journal of Clinical Medicine</i> , 2020, 9, 2560.	1.0	16
101	Novel Imaging Strategies in Systemic Sclerosis. <i>Current Rheumatology Reports</i> , 2020, 22, 57.	2.1	1
102	New lessons for an old problem: ASSET open-label extension. <i>Lancet Rheumatology</i> , The, 2020, 2, e726-e727.	2.2	0

#	ARTICLE	IF	CITATIONS
103	The power of the EUSTAR cohort: key findings to date and implications for management of systemic sclerosis patients. <i>Expert Review of Clinical Immunology</i> , 2020, 16, 1065-1074.	1.3	5
104	Response to: "Correspondence on "Safety and tolerability of nintedanib in patients with systemic sclerosis-associated interstitial lung disease: data from the SENSICIS trial" by Bredemeier. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, e251-e251.	0.5	0
105	Potential Biomarkers in Systemic Sclerosis: A Literature Review and Update. <i>Journal of Clinical Medicine</i> , 2020, 9, 3388.	1.0	24
106	Dermal fibroblasts have different extracellular matrix profiles induced by TGF- $\beta$ 2, PDGF and IL-6 in a model for skin fibrosis. <i>Scientific Reports</i> , 2020, 10, 17300.	1.6	54
107	HRCT evaluation of patients with interstitial lung disease: comparison of the 2018 and 2011 diagnostic guidelines. <i>Therapeutic Advances in Respiratory Disease</i> , 2020, 14, 175346662096849.	1.0	12
108	Current and emerging treatment options for lung cancer in patients with pre-existing connective tissue disease. <i>Pulmonary Pharmacology and Therapeutics</i> , 2020, 63, 101937.	1.1	2
109	Response to: "Riociguat in systemic sclerosis: a potential for disease modification" by Jain and Dhir. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, e117-e117.	0.5	0
110	ILD-specific health-related quality of life in systemic sclerosis-associated ILD compared with IPF. <i>BMJ Open Respiratory Research</i> , 2020, 7, e000598.	1.2	11
111	Progressive fibrosing interstitial lung disease: clinical uncertainties, consensus recommendations, and research priorities. <i>Lancet Respiratory Medicine</i> , 2020, 8, 925-934.	5.2	198
112	Mycophenolate Mofetil Improves Exercise Tolerance in Systemic Sclerosis Patients with Interstitial Lung Disease: A Pilot Study. <i>Rheumatology and Therapy</i> , 2020, 7, 1037-1044.	1.1	2
114	Novel Multitarget Therapies for Lung Cancer and Respiratory Disease. <i>Molecules</i> , 2020, 25, 3987.	1.7	14
115	Extended Exhaled Nitric Oxide Analysis in Interstitial Lung Diseases: A Systematic Review. <i>International Journal of Molecular Sciences</i> , 2020, 21, 6187.	1.8	15
116	Evolution of interstitial lung disease one year after hematopoietic stem cell transplantation or cyclophosphamide for systemic sclerosis. <i>Arthritis Care and Research</i> , 2020, , .	1.5	13
117	Diagnostic and prognostic markers and treatment of connective tissue disease-associated pulmonary arterial hypertension: current recommendations and recent advances. <i>Expert Review of Clinical Immunology</i> , 2020, 16, 993-1004.	1.3	7
118	A randomised, double-blind, placebo-controlled, 24-week, phase II, proof-of-concept study of romilkimab (SAR156597) in early diffuse cutaneous systemic sclerosis. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 1600-1607.	0.5	69
119	Tocilizumab in systemic sclerosis: a randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet Respiratory Medicine</i> , 2020, 8, 963-974.	5.2	348
121	Prevalence of Novel Myositis Autoantibodies in a Large Cohort of Patients with Interstitial Lung Disease. <i>Journal of Clinical Medicine</i> , 2020, 9, 2944.	1.0	12
123	Cell Therapy for Idiopathic Pulmonary Fibrosis: Rationale and Progress to Date. <i>BioDrugs</i> , 2020, 34, 543-556.	2.2	8

#	ARTICLE	IF	CITATIONS
124	Efficacy and safety of imatinib mesylate in systemic sclerosis. A systematic review and meta-analysis. Expert Review of Clinical Immunology, 2020, 16, 931-942.	1.3	5
126	Lung complications of Sjogren syndrome. European Respiratory Review, 2020, 29, 200021.	3.0	31
127	A new nucleosomic-based model to identify and diagnose SSc-ILD. Clinical Epigenetics, 2020, 12, 124.	1.8	3
128	Gender equity in interstitial lung disease. Lancet Respiratory Medicine, 2020, 8, 842-843.	5.2	6
129	Infections and systemic sclerosis: an emerging challenge. Revista Colombiana De Reumatología (English Edition), 2020, 27, 62-84.	0.1	1
130	Serum metabolites as biomarkers in systemic sclerosis-associated interstitial lung disease. Scientific Reports, 2020, 10, 21912.	1.6	9
132	Toward Realizing the Full Potential of Registries in Interstitial Lung Disease. Annals of the American Thoracic Society, 2020, 17, 1534-1535.	1.5	0
133	Therapeutic options for patients with rare rheumatic diseases: a systematic review and meta-analysis. Orphanet Journal of Rare Diseases, 2020, 15, 308.	1.2	2
134	Current Therapeutic Approaches in Scleroderma: Clinical Models of Effective Antifibrotic Therapies. Current Treatment Options in Rheumatology, 2020, 6, 382-393.	0.6	1
135	Inhaled nintedanib is well-tolerated and delivers key pharmacokinetic parameters required to treat bleomycin-induced pulmonary fibrosis. Pulmonary Pharmacology and Therapeutics, 2020, 63, 101938.	1.1	20
137	Underdetection of Interstitial Lung Disease in Juvenile Systemic Sclerosis. Arthritis Care and Research, 2022, 74, 364-370.	1.5	13
138	Interleukin-31 promotes pathogenic mechanisms underlying skin and lung fibrosis in scleroderma. Rheumatology, 2020, 59, 2625-2636.	0.9	33
139	Clinical characteristics and outcomes of 566 Thais with systemic sclerosis: A cohort study. International Journal of Rheumatic Diseases, 2020, 23, 945-957.	0.9	22
140	Treatment With Mycophenolate and Cyclophosphamide Leads to Clinically Meaningful Improvements in Patient-Reported Outcomes in Scleroderma Lung Disease: Results of Scleroderma Lung Study II. ACR Open Rheumatology, 2020, 2, 362-370.	0.9	31
141	Survival and course of lung function in the presence or absence of antifibrotic treatment in patients with idiopathic pulmonary fibrosis: long-term results of the INSIGHTS-IPF registry. European Respiratory Journal, 2020, 56, 1902279.	3.1	102
142	The world is not enough – the value of increasing registry data in idiopathic pulmonary fibrosis. Respiratory Research, 2020, 21, 105.	1.4	3
143	Improving risk-stratification of rheumatoid arthritis patients for interstitial lung disease. PLoS ONE, 2020, 15, e0232978.	1.1	26
144	Refractory Sarcoidosis: A Review. Therapeutics and Clinical Risk Management, 2020, Volume 16, 323-345.	0.9	50



#	ARTICLE	IF	CITATIONS
145	Update in Interstitial Lung Disease 2019. American Journal of Respiratory and Critical Care Medicine, 2020, 202, 500-507.	2.5	17
146	European consensus statements for interstitial lung disease in systemic sclerosis. Lancet Rheumatology, The, 2020, 2, e317-e318.	2.2	1
147	European consensus statements for interstitial lung disease in systemic sclerosis. Lancet Rheumatology, The, 2020, 2, e318-e319.	2.2	0
148	European consensus statements for interstitial lung disease in systemic sclerosis – Authors' reply. Lancet Rheumatology, The, 2020, 2, e319-e320.	2.2	4
149	A new therapy for systemic sclerosis-associated interstitial lung disease. Respiratory Investigation, 2020, 58, 227-229.	0.9	0
150	Polyporus Polysaccharide Ameliorates Bleomycin-Induced Pulmonary Fibrosis by Suppressing Myofibroblast Differentiation via TGF- $\beta$ 2/Smad2/3 Pathway. Frontiers in Pharmacology, 2020, 11, 767.	1.6	16
151	Nintedanib for the treatment of systemic sclerosis-associated interstitial lung disease. Expert Review of Clinical Immunology, 2020, 16, 547-560.	1.3	5
152	Autoantibodies to stratify systemic sclerosis patients into clinically actionable subsets. Autoimmunity Reviews, 2020, 19, 102583.	2.5	25
153	The extended utility of antifibrotic therapy in progressive fibrosing interstitial lung disease. Expert Review of Respiratory Medicine, 2020, 14, 1001-1008.	1.0	6
154	Current and Potential New Targets in Systemic Sclerosis Therapy: a New Hope. Current Rheumatology Reports, 2020, 22, 42.	2.1	32
155	Decreased serum cathepsin S levels in patients with systemic sclerosis-associated interstitial lung disease. Journal of Dermatology, 2020, 47, 1027-1032.	0.6	4
156	Expert Perspectives On Clinical Challenges: Expert Perspectives: Challenges in Scleroderma. Arthritis and Rheumatology, 2020, 72, 1415-1426.	2.9	0
157	Combined anti-fibrotic and anti-inflammatory properties of JAK-inhibitors on macrophages in vitro and in vivo: Perspectives for scleroderma-associated interstitial lung disease. Biochemical Pharmacology, 2020, 178, 114103.	2.0	82
158	Comment on: Skin improvement is a surrogate for favourable changes in other organ systems in early diffuse cutaneous systemic sclerosis. Rheumatology, 2020, 59, 1782-1783.	0.9	1
159	Drugs in phase I and phase II clinical trials for systemic sclerosis. Expert Opinion on Investigational Drugs, 2020, 29, 349-362.	1.9	10
160	Prominence of IL6, IGF, TLR, and Bioenergetics Pathway Perturbation in Lung Tissues of Scleroderma Patients With Pulmonary Fibrosis. Frontiers in Immunology, 2020, 11, 383.	2.2	40
161	Pathogenesis of systemic sclerosis associated interstitial lung disease. Journal of Scleroderma and Related Disorders, 2020, 5, 6-16.	1.0	53
162	Hope in Patients With Progressive Fibrosis Interstitial Lung Disease (PF-ILD). Clinical Pulmonary Medicine, 2020, 27, 38-38.	0.3	0

#	ARTICLE	IF	CITATIONS
163	The Prophylactic Use of Macrolide Antibiotics to Prevent Acute Exacerbations in Bronchiectasis. <i>Clinical Pulmonary Medicine</i> , 2020, 27, 37-38.	0.3	0
164	Treatment of systemic sclerosis-associated interstitial lung disease: Lessons from clinical trials. <i>Journal of Scleroderma and Related Disorders</i> , 2020, 5, 61-71.	1.0	43
165	Progress in the treatment of pulmonary fibrosis. <i>Lancet Respiratory Medicine</i> , 2020, 8, 424-425.	5.2	9
166	Randomised controlled trials in systemic sclerosis: patient selection and endpoints for next generation trials. <i>Lancet Rheumatology</i> , 2020, 2, e173-e184.	2.2	12
167	Contemporary Concise Review 2019: Interstitial lung disease. <i>Respirology</i> , 2020, 25, 756-763.	1.3	2
168	A Defect in Thymic Tolerance Causes T Cell-Mediated Autoimmunity in a Murine Model of COPA Syndrome. <i>Journal of Immunology</i> , 2020, 204, 2360-2373.	0.4	28
169	Management of systemic sclerosis: the first five years. <i>Current Opinion in Rheumatology</i> , 2020, 32, 228-237.	2.0	38
170	Management of ANCA associated vasculitis. <i>BMJ</i> , 2020, 368, m421.	3.0	54
171	Effects of Nintedanib in an Animal Model of Liver Fibrosis. <i>BioMed Research International</i> , 2020, 2020, 1-9.	0.9	19
172	Efficacy and safety of pirfenidone in systemic sclerosis-related interstitial lung disease—a randomised controlled trial. <i>Rheumatology International</i> , 2020, 40, 703-710.	1.5	64
173	Derivation and Validation of a Diagnostic Prediction Tool for Interstitial Lung Disease. <i>Chest</i> , 2020, 158, 620-629.	0.4	9
174	Current and Future Outlook on Disease Modification and Defining Low Disease Activity in Systemic Sclerosis. <i>Arthritis and Rheumatology</i> , 2020, 72, 1049-1058.	2.9	27
175	Nintedanib in patients with progressive fibrosing interstitial lung diseases—subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trial. <i>Lancet Respiratory Medicine</i> , 2020, 8, 453-460.	5.2	331
176	Interstitial lung abnormalities detected incidentally on CT: a Position Paper from the Fleischner Society. <i>Lancet Respiratory Medicine</i> , 2020, 8, 726-737.	5.2	279
177	Safety and efficacy of abatacept in patients with treatment-resistant SARCoidosis (ABASARC) — protocol for a multi-center, single-arm phase IIa trial. <i>Contemporary Clinical Trials Communications</i> , 2020, 19, 100575.	0.5	10
178	Connective tissue disease-associated interstitial lung disease. <i>Pulmonology</i> , 2022, 28, 113-118.	1.0	23
179	Novel Therapeutic Approaches for Pulmonary Manifestations of Systemic Sclerosis. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2020, 202, 878-880.	2.5	0
180	Trends in systemic sclerosis and systemic sclerosis-related pulmonary arterial hypertension mortality in the USA. <i>ERJ Open Research</i> , 2020, 6, 00309-2019.	1.1	6

#	ARTICLE	IF	CITATIONS
181	Pulmonary Hypertension Phenotypes in Systemic Sclerosis: The Right Diagnosis for the Right Treatment. <i>International Journal of Molecular Sciences</i> , 2020, 21, 4430.	1.8	20
182	Progressive fibrosing interstitial lung disease: we know it behaves badly, but what does that mean?. <i>European Respiratory Journal</i> , 2020, 55, 2000894.	3.1	1
183	Progressive Fibrosing Interstitial Lung Disease. A Proposed Integrated Algorithm for Management. <i>Annals of the American Thoracic Society</i> , 2020, 17, 1199-1203.	1.5	6
184	Recommendations for the Treatment of Systemic Sclerosis: Agreement May Not Translate into Uptake. <i>Journal of Rheumatology</i> , 2020, 47, 164-165.	1.0	1
185	Real-world appropriateness of imaging severity thresholds in interstitial lung disease clinical trials. <i>Lancet Respiratory Medicine</i> , 2020, 8, e7.	5.2	1
186	Therapeutic Options for the Treatment of Interstitial Lung Disease Related to Connective Tissue Diseases. A Narrative Review. <i>Journal of Clinical Medicine</i> , 2020, 9, 407.	1.0	40
187	Antibody-based therapies for idiopathic pulmonary fibrosis. <i>Expert Opinion on Biological Therapy</i> , 2020, 20, 779-786.	1.4	13
188	Predictors of progression in systemic sclerosis patients with interstitial lung disease. <i>European Respiratory Journal</i> , 2020, 55, 1902026.	3.1	134
189	The future of treatment in systemic sclerosis: can we design better trials?. <i>Lancet Rheumatology</i> , 2020, 2, e185-e194.	2.2	10
190	Multidimensional tracking of phenotypes and organ involvement in a complete nationwide systemic sclerosis cohort. <i>Rheumatology</i> , 2020, 59, 2920-2929.	0.9	28
191	Targeted therapies in systemic sclerosis, myositis, antiphospholipid syndrome, and Sjögren's syndrome. <i>Best Practice and Research in Clinical Rheumatology</i> , 2020, 34, 101485.	1.4	11
192	TGF- $\beta$ 2 pathway activation by idiopathic pulmonary fibrosis (IPF) fibroblast derived soluble factors is mediated by IL-6 trans-signaling. <i>Respiratory Research</i> , 2020, 21, 56.	1.4	90
193	Systemic sclerosis-associated interstitial lung disease. <i>Lancet Respiratory Medicine</i> , 2020, 8, 304-320.	5.2	202
194	Imaging research in fibrotic lung disease; applying deep learning to unsolved problems. <i>Lancet Respiratory Medicine</i> , 2020, 8, 1144-1153.	5.2	47
195	Challenges in evidence-based therapy for systemic sclerosis associated interstitial lung disease. <i>Lancet Respiratory Medicine</i> , 2020, 8, 226-227.	5.2	2
196	An Open-label Study With Pirfenidone on Chronic Hypersensitivity Pneumonitis. <i>Archivos De Bronconeumologia</i> , 2020, 56, 163-169.	0.4	7
197	Management of systemic sclerosis-associated interstitial lung disease in the current era. <i>International Journal of Rheumatic Diseases</i> , 2020, 23, 137-139.	0.9	6
198	Lung function is associated with minimal EQ-5D changes over time in patients with systemic sclerosis. <i>Clinical Rheumatology</i> , 2020, 39, 1543-1549.	1.0	4

#	ARTICLE	IF	CITATIONS
199	The identification and management of interstitial lung disease in systemic sclerosis: evidence-based European consensus statements. <i>Lancet Rheumatology</i> , The, 2020, 2, e71-e83.	2.2	182
200	Systemic sclerosis: Advances towards stratified medicine. <i>Best Practice and Research in Clinical Rheumatology</i> , 2020, 34, 101469.	1.4	9
201	Therapeutic molecular targets of SSc-ILD. <i>Journal of Scleroderma and Related Disorders</i> , 2020, 5, 17-30.	1.0	6
202	Inflammatory Myopathy-Related Interstitial Lung Disease: From Pathophysiology to Treatment. <i>Frontiers in Medicine</i> , 2019, 6, 326.	1.2	43
203	Circulating lung biomarkers in idiopathic lung fibrosis and interstitial lung diseases associated with connective tissue diseases: Where do we stand?. <i>Seminars in Arthritis and Rheumatism</i> , 2020, 50, 480-491.	1.6	41
206	Interstitial lung disease. <i>Canadian Journal of Respiratory, Critical Care, and Sleep Medicine</i> , 2020, 4, S21-S24.	0.2	0
209	Evolution of high-resolution CT-scan in systemic sclerosis-associated interstitial lung disease: Description and prognosis factors. <i>Seminars in Arthritis and Rheumatism</i> , 2020, 50, 1406-1413.	1.6	11
210	Nonspecific Interstitial Pneumonia. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2020, 41, 184-201.	0.8	7
211	Quantification of Ground Glass Opacities Can Be Useful to Describe Disease Activity in Systemic Sclerosis. <i>Diagnostics</i> , 2020, 10, 225.	1.3	4
212	Management issues in rheumatoid arthritis-associated interstitial lung disease. <i>Current Opinion in Rheumatology</i> , 2020, 32, 255-263.	2.0	39
213	Diurnal variation in forced vital capacity in patients with fibrotic interstitial lung disease using home spirometry. <i>ERJ Open Research</i> , 2020, 6, 00054-2020.	1.1	17
214	<p>Management of Pulmonary Arterial Hypertension in Patients with Systemic Sclerosis</p>. <i>Integrated Blood Pressure Control</i> , 2020, Volume 13, 15-29.	0.4	24
215	Healthcare Resource Utilization Among Patients in England with Systemic Sclerosis-Associated Interstitial Lung Disease: A Retrospective Database Analysis. <i>Advances in Therapy</i> , 2020, 37, 2460-2476.	1.3	10
216	Practical Considerations for the Diagnosis and Treatment of Fibrotic Interstitial Lung Disease During the Coronavirus Disease 2019 Pandemic. <i>Chest</i> , 2020, 158, 1069-1078.	0.4	57
217	Pirfenidone for the treatment of interstitial lung disease associated to rheumatoid arthritis: a new scenario is coming?. <i>Respiratory Medicine Case Reports</i> , 2020, 30, 101051.	0.2	4
218	Lung cryobiopsy and interstitial lung disease: What is its role in the era of multidisciplinary meetings and antifibrotics?. <i>Respirology</i> , 2020, 25, 987-996.	1.3	9
219	Riociguat in patients with early diffuse cutaneous systemic sclerosis (RISE-SSc): randomised, double-blind, placebo-controlled multicentre trial. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 618-625.	0.5	71
220	Patient and Physician Perspectives on Systemic Sclerosis-Associated Interstitial Lung Disease. <i>Clinical Medicine Insights: Circulatory, Respiratory and Pulmonary Medicine</i> , 2020, 14, 117954842091328.	0.5	9

#	ARTICLE	IF	CITATIONS
221	Patient-reported outcome measures in systemic sclerosis-related interstitial lung disease for clinical practice and clinical trials. <i>Journal of Scleroderma and Related Disorders</i> , 2020, 5, 48-60.	1.0	13
222	Recent progress and missing gaps to achieve goal in the care of systemic sclerosis-associated interstitial lung disease. <i>Journal of Scleroderma and Related Disorders</i> , 2020, 5, 3-5.	1.0	9
223	Vascular permeability in the fibrotic lung. <i>European Respiratory Journal</i> , 2020, 56, 1900100.	3.1	52
224	Familial Interstitial Lung Disease. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2020, 41, 229-237.	0.8	10
225	Nintedanib in patients with systemic sclerosis-associated interstitial lung disease: A Japanese population analysis of the SENSICIS trial. <i>Modern Rheumatology</i> , 2021, 31, 141-150.	0.9	14
226	The Challenge of Very Early Systemic Sclerosis: A Combination of Mild and Early Disease?. <i>Journal of Rheumatology</i> , 2021, 48, 82-86.	1.0	15
227	Effect of Nintedanib on Lung Function in Patients With Systemic Sclerosis-Associated Interstitial Lung Disease: Further Analyses of a Randomized, Double-blind, Placebo-controlled Trial. <i>Arthritis and Rheumatology</i> , 2021, 73, 671-676.	2.9	24
228	Economic Burden and Management of Systemic Sclerosis-Associated Interstitial Lung Disease in 8 European Countries: The BUILDup Delphi Consensus Study. <i>Advances in Therapy</i> , 2021, 38, 521-540.	1.3	9
229	Disease frequency, patient characteristics, comorbidity outcomes and immunosuppressive therapy in systemic sclerosis and systemic sclerosis-associated interstitial lung disease: a US cohort study. <i>Rheumatology</i> , 2021, 60, 1915-1925.	0.9	15
230	Rituximab in the treatment of systemic sclerosis-related interstitial lung disease: a systematic review and meta-analysis. <i>Rheumatology</i> , 2021, 60, 557-567.	0.9	61
231	Chest wall muscle atrophy as a contributory factor for forced vital capacity decline in systemic sclerosis-associated interstitial lung disease. <i>Rheumatology</i> , 2021, 60, 250-255.	0.9	12
232	Données récentes sur la prise en charge clinique de la sclérodémie systémique. <i>Revue Du Rhumatisme (Edition Française)</i> , 2021, 88, 24-31.	0.0	0
233	Mechanisms of progressive fibrosis in connective tissue disease (CTD)-associated interstitial lung diseases (ILDs). <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 143-150.	0.5	120
234	Considerations for a combined index for limited cutaneous systemic sclerosis to support drug development and improve outcomes. <i>Journal of Scleroderma and Related Disorders</i> , 2021, 6, 66-76.	1.0	12
235	Progressive interstitial lung disease in patients with systemic sclerosis-associated interstitial lung disease in the EUSTAR database. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 219-227.	0.5	160
237	Feasibility of online home spirometry in systemic sclerosis-associated interstitial lung disease: a pilot study. <i>Rheumatology</i> , 2021, 60, 2467-2471.	0.9	19
238	New composite endpoint in early diffuse cutaneous systemic sclerosis: revisiting the provisional American College of Rheumatology Composite Response Index in Systemic Sclerosis. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 641-650.	0.5	25
239	Beneficial impact of weight loss on respiratory function in interstitial lung disease patients with obesity. <i>Respiratory Investigation</i> , 2021, 59, 247-251.	0.9	9

#	ARTICLE	IF	CITATIONS
240	Diagnosis and management of connective tissue disease-associated interstitial lung disease in Australia and New Zealand: A position statement from the Thoracic Society of Australia and New Zealand*. <i>Respirology</i> , 2021, 26, 23-51.	1.3	45
241	Systemic Sclerosis: A Comprehensive Approach to Diagnosis and Management. <i>Physician Assistant Clinics</i> , 2021, 6, 159-175.	0.1	0
242	Efficacy and safety of nintedanib in Asian patients with systemic sclerosis-associated interstitial lung disease: Subgroup analysis of the SENSCLIS trial. <i>Respiratory Investigation</i> , 2021, 59, 252-259.	0.9	15
243	Review of indications for immunoglobulin (IG) use: Narrowing the gap between supply and demand. <i>Transfusion Clinique Et Biologique</i> , 2021, 28, 96-122.	0.2	26
244	Current monitoring and treatment of progressive fibrosing interstitial lung disease: a survey of physicians in Japan, the United States, and the European Union. <i>Current Medical Research and Opinion</i> , 2021, 37, 327-339.	0.9	5
245	Targeted therapies in interstitial lung disease secondary to systemic autoimmune rheumatic disease. Current status and future development. <i>Autoimmunity Reviews</i> , 2021, 20, 102742.	2.5	8
247	Serum markers of pulmonary epithelial damage in systemic sclerosis-associated interstitial lung disease and disease progression. <i>Respirology</i> , 2021, 26, 461-468.	1.3	30
248	Using quantitative computed tomography to predict mortality in patients with interstitial lung disease related to systemic sclerosis: implications for personalized medicine. <i>Expert Review of Precision Medicine and Drug Development</i> , 2021, 6, 31-40.	0.4	1
249	Predictive Significance of Serum Interferon-Inducible Protein Score for Response to Treatment in Systemic Sclerosis-Related Interstitial Lung Disease. <i>Arthritis and Rheumatology</i> , 2021, 73, 1005-1013.	2.9	21
250	Racial Disparities in Systemic Sclerosis: Short- and Long-Term Outcomes Among African American Participants of SLS I and II. <i>ACR Open Rheumatology</i> , 2021, 3, 8-16.	0.9	7
251	Leukocyte telomere length and mycophenolate therapy in chronic hypersensitivity pneumonitis. <i>European Respiratory Journal</i> , 2021, 57, 2002872.	3.1	32
252	Progressive fibrosing interstitial lung disease: a clinical cohort (the PROGRESS study). <i>European Respiratory Journal</i> , 2021, 57, 2002718.	3.1	103
253	Progressive fibrosing interstitial lung diseases: A new concept and indication of nintedanib. <i>Modern Rheumatology</i> , 2021, 31, 13-19.	0.9	20
254	Autologous stem-cell transplantation in systemic sclerosis-associated interstitial lung disease: early action in selected patients rather than escalation therapy for all. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2021, 13, 1759720X2110351.	1.2	8
255	Antifibrotic Therapy: Is There a Role in Myositis-Interstitial Lung Disease?. <i>Respiration</i> , 2021, 100, 923-932.	1.2	1
256	Clinical Treatment Options in Scleroderma: Recommendations and Comprehensive Review. <i>Clinical Reviews in Allergy and Immunology</i> , 2022, 62, 273-291.	2.9	28
257	Monitoring and management of fibrosing interstitial lung diseases: a narrative review for practicing clinicians. <i>Therapeutic Advances in Respiratory Disease</i> , 2021, 15, 175346662110397.	1.0	11
258	The evolution of the <i>European Respiratory Journal</i> : weathering the publishing pandemic. <i>European Respiratory Journal</i> , 2021, 57, 2100084.	3.1	3

#	ARTICLE	IF	CITATIONS
259	Assessment of recent evidence for the management of patients with systemic sclerosis-associated interstitial lung disease: a systematic review. <i>ERJ Open Research</i> , 2021, 7, 00235-2020.	1.1	11
260	Treatment Initiation in Patients with Interstitial Lung Disease in Canada. <i>Annals of the American Thoracic Society</i> , 2021, 18, 1661-1668.	1.5	4
261	Immunmodulation bei autoimmunen interstitiellen Lungenerkrankungen. <i>Karger Kompass Autoimmun</i> , 2021, 3, 2-9.	0.0	0
262	Successful treatment of severe interstitial pneumonia by removal of circulating autoantibodies: a case series. <i>BMC Pulmonary Medicine</i> , 2021, 21, 13.	0.8	3
263	Diagnostic and Therapeutic Applications of Extracellular Vesicles in Interstitial Lung Diseases. <i>Diagnostics</i> , 2021, 11, 87.	1.3	5
264	New insights into the treatment of CTD-ILD. <i>Nature Reviews Rheumatology</i> , 2021, 17, 79-80.	3.5	14
265	Experience With Nintedanib in Severe Pulmonary Fibrosis Associated With Systemic Sclerosis: A Case Series. <i>Open Respiratory Archives</i> , 2021, 3, 100080.	0.0	3
267	Sklerodermie bei Kindern und Jugendlichen. <i>Springer Reference Medizin</i> , 2021, , 1-21.	0.0	0
268	Weiterentwicklung in der Therapie rheumatischer Erkrankungen bei Kindern und Jugendlichen. <i>Springer Reference Medizin</i> , 2021, , 1-19.	0.0	0
269	Interstitial lung abnormality (ILA) and nonspecific interstitial pneumonia (NSIP). <i>European Journal of Radiology Open</i> , 2021, 8, 100336.	0.7	8
270	ERS International Congress 2020: highlights from the Thoracic Surgery and Transplantation Assembly. <i>ERJ Open Research</i> , 2021, 7, 00743-2020.	1.1	0
272	Efficacy and safety of nintedanib in patients with systemic sclerosis-associated interstitial lung disease treated with mycophenolate: a subgroup analysis of the SENSICIS trial. <i>Lancet Respiratory Medicine</i> , 2021, 9, 96-106.	5.2	118
273	Efficacy and Tolerability of Nintedanib in Idiopathic-Inflammatory-Myopathy-Related Interstitial Lung Disease: A Pilot Study. <i>Frontiers in Medicine</i> , 2021, 8, 626953.	1.2	17
274	Identifying unmet needs in SSc-ILD by semi-qualitative in-depth interviews. <i>Rheumatology</i> , 2021, 60, 5601-5609.	0.9	10
275	Use of nintedanib in interstitial lung disease other than idiopathic pulmonary fibrosis: much caution is warranted. <i>Pulmonary Pharmacology and Therapeutics</i> , 2021, 66, 101987.	1.1	6
276	Engineering Advanced In Vitro Models of Systemic Sclerosis for Drug Discovery and Development. <i>Advanced Biology</i> , 2021, 5, e2000168.	1.4	8
277	The multifaceted problem of pulmonary arterial hypertension in systemic sclerosis. <i>Lancet Rheumatology</i> , 2021, 3, e149-e159.	2.2	11
280	Hermansky-Pudlak syndrome pulmonary fibrosis: a rare inherited interstitial lung disease. <i>European Respiratory Review</i> , 2021, 30, 200193.	3.0	18

#	ARTICLE	IF	CITATIONS
281	The rationale for targeting the JAK/STAT pathway in scleroderma-associated interstitial lung disease. <i>Immunotherapy</i> , 2021, 13, 241-256.	1.0	16
282	The Treatment of Lung Involvement in Systemic Sclerosis. <i>Pharmaceuticals</i> , 2021, 14, 154.	1.7	13
283	Interstitial lung disease in systemic sclerosis (systemic scleroderma). <i>Sovremennaya Revmatologiya</i> , 2021, 15, 1-62.	0.1	2
284	Detection and Management of Interstitial Lung Diseases Associated With Connective Tissue Diseases. <i>ACR Open Rheumatology</i> , 2021, 3, 295-304.	0.9	9
285	Natural variability in the disease course of SSc-ILD: implications for treatment. <i>European Respiratory Review</i> , 2021, 30, 200340.	3.0	18
286	<sup>68</sup> Ga-FAPI-04 PET-CT for molecular assessment of fibroblast activation and risk evaluation in systemic sclerosis-associated interstitial lung disease: a single-centre, pilot study. <i>Lancet Rheumatology</i> , The, 2021, 3, e185-e194.	2.2	46
287	Nintedanib: A Review in Fibrotic Interstitial Lung Diseases. <i>Drugs</i> , 2021, 81, 575-586.	4.9	51
288	Computed Tomography Findings as Determinants of Local and Systemic Inflammation Biomarkers in Interstitial Lung Diseases: A Retrospective Registry-Based Descriptive Study. <i>Lung</i> , 2021, 199, 155-164.	1.4	5
289	Pharmacological Interventions for Pulmonary Involvement in Rheumatic Diseases. <i>Pharmaceuticals</i> , 2021, 14, 251.	1.7	2
290	Quality evaluation of the underlying evidence in the updated treatment recommendations for systemic lupus erythematosus. <i>Rheumatology</i> , 2021, , .	0.9	1
291	Progression in the Management of Non-Idiopathic Pulmonary Fibrosis Interstitial Lung Diseases, Where Are We Now and Where We Would Like to Be. <i>Journal of Clinical Medicine</i> , 2021, 10, 1330.	1.0	11
292	The Diagnosis and Treatment of Pulmonary Fibrosis. <i>Deutsches A&amp;#x0308;rztblatt International</i> , 2021, 118, .	0.6	10
293	A mixed-methods pilot study of handheld fan for breathlessness in interstitial lung disease. <i>Scientific Reports</i> , 2021, 11, 6874.	1.6	8
294	Pharmacological treatment of idiopathic pulmonary fibrosis and fibrosing interstitial lung diseases: current trends and future directions. <i>Precision and Future Medicine</i> , 2021, 5, 31-40.	0.5	2
295	Study design of a randomised, placebo-controlled trial of nintedanib in children and adolescents with fibrosing interstitial lung disease. <i>ERJ Open Research</i> , 2021, 7, 00805-2020.	1.1	14
296	<sup>18</sup> F-FDG positron emission tomography scanning in systemic sclerosis-associated interstitial lung disease: a pilot study. <i>Arthritis Research and Therapy</i> , 2021, 23, 76.	1.6	20
297	Nintedanib and immunomodulatory therapies in progressive fibrosing interstitial lung diseases. <i>Respiratory Research</i> , 2021, 22, 84.	1.4	33
298	Treatment for systemic sclerosis-associated interstitial lung disease. <i>Current Opinion in Rheumatology</i> , 2021, 33, 240-248.	2.0	27



#	ARTICLE	IF	CITATIONS
299	Cardiovascular safety of the tyrosine kinase inhibitor nintedanib. <i>British Journal of Clinical Pharmacology</i> , 2021, 87, 3690-3698.	1.1	8
300	Interstitial Lung Disease Worsens Short- and Long-Term Outcomes of Systemic Rheumatic Disease Patients Admitted to the ICU: A Multicenter Study. <i>Journal of Clinical Medicine</i> , 2021, 10, 1037.	1.0	1
301	Interstitial Pneumonia Secondary to Hermansky-Pudlak Syndrome Type 4 Treated with Different Antifibrotic Agents. <i>Internal Medicine</i> , 2021, 60, 783-788.	0.3	3
302	Domains and outcome measures for the assessment of limited cutaneous systemic sclerosis: a scoping review protocol. <i>BMJ Open</i> , 2021, 11, e044765.	0.8	6
303	The Effect of Nintedanib on T-Cell Activation, Subsets and Functions. <i>Drug Design, Development and Therapy</i> , 2021, Volume 15, 997-1011.	2.0	11
304	Disparate Interferon Signaling and Shared Aberrant Basaloid Cells in Single-Cell Profiling of Idiopathic Pulmonary Fibrosis and Systemic Sclerosis-Associated Interstitial Lung Disease. <i>Frontiers in Immunology</i> , 2021, 12, 595811.	2.2	54
305	Diagnosis and Management of Interstitial Lung Disease in Patients with Connective Tissue Diseases. <i>Case Reports in Rheumatology</i> , 2021, 2021, 1-7.	0.2	1
306	Sjögren's syndrome"summary of clinical management. , 2021, , 255-268.		0
307	Clinical characteristics of non-idiopathic pulmonary fibrosis, progressive fibrosing interstitial lung diseases. <i>Medicine (United States)</i> , 2021, 100, e25322.	0.4	8
308	Impact of bronchoalveolar lavage lymphocytosis on the effects of anti-inflammatory therapy in idiopathic non-specific interstitial pneumonia, idiopathic pleuroparenchymal fibroelastosis, and unclassifiable idiopathic interstitial pneumonia. <i>Respiratory Research</i> , 2021, 22, 115.	1.4	5
309	Evaluation of a novel particle-based multi-analyte technology for the detection of anti-fibrillar antibodies. <i>Immunologic Research</i> , 2021, 69, 239-248.	1.3	5
312	Exposure-efficacy analyses of nintedanib in patients with chronic fibrosing interstitial lung disease. <i>Respiratory Medicine</i> , 2021, 180, 106369.	1.3	9
313	Current advances in the treatment of autoimmune-associated interstitial lung diseases. <i>Journal of the Korean Medical Association</i> , 2021, 64, 264-276.	0.1	0
314	Pulmonary arterial hypertension in systemic sclerosis. <i>Presse Medicale</i> , 2021, 50, 104062.	0.8	6
315	ANCA Status or Clinical Phenotype "What Counts More?. <i>Current Rheumatology Reports</i> , 2021, 23, 37.	2.1	14
316	Chronic Lung Allograft Dysfunction: Evolving Concepts and Therapies. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2021, 42, 392-410.	0.8	4
317	Comparison of the effectiveness of cyclophosphamide and rituximab treatment in patients with systemic sclerosis-related interstitial lung diseases: a retrospective, observational cohort study. <i>Clinical Rheumatology</i> , 2021, 40, 4071-4079.	1.0	4
318	An updated safety review of the drug treatments for idiopathic pulmonary fibrosis. <i>Expert Opinion on Drug Safety</i> , 2021, 20, 1035-1048.	1.0	6

#	ARTICLE	IF	CITATIONS
319	Inflammatory profile of induced sputum composition in systemic sclerosis and comparison with healthy volunteers. <i>Scientific Reports</i> , 2021, 11, 10679.	1.6	6
320	Depletion of Numb and Numbl like in Murine Lung Epithelial Cells Ameliorates Bleomycin-Induced Lung Fibrosis by Inhibiting the $\beta$ -Catenin Signaling Pathway. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 639162.	1.8	5
321	Baseline plasma KL-6 level predicts adverse outcomes in patients with idiopathic pulmonary fibrosis receiving nintedanib: a retrospective real-world cohort study. <i>BMC Pulmonary Medicine</i> , 2021, 21, 165.	0.8	9
322	Recent advances in the diagnosis and management of interstitial pneumonia with autoimmune features: the perspective of rheumatologists. <i>Korean Journal of Internal Medicine</i> , 2021, 36, 515-526.	0.7	3
323	The target on B cells in Systemic Sclerosis: a "midsummer dream" to extinguish inflammation and prevent early disease progression to fibrosis. <i>Clinical Rheumatology</i> , 2021, 40, 2529-2533.	1.0	5
324	Antifibrotic Therapies and Progressive Fibrosing Interstitial Lung Disease (PF-ILD): Building on INBUILD. <i>Journal of Clinical Medicine</i> , 2021, 10, 2285.	1.0	18
325	Tocilizumab Prevents Progression of Early Systemic Sclerosis-Associated Interstitial Lung Disease. <i>Arthritis and Rheumatology</i> , 2021, 73, 1301-1310.	2.9	104
326	New promising drugs for the treatment of systemic sclerosis: pathogenic considerations, enhanced classifications, and personalized medicine. <i>Expert Opinion on Investigational Drugs</i> , 2021, 30, 635-652.	1.9	28
327	Pulmonary Involvement at Connective Tissue Systemic Diseases in Children. <i>Voprosy Sovremennoi Pediatrii - Current Pediatrics</i> , 2021, 20, 134-143.	0.1	0
328	Ground glass and fibrotic change in children with surfactant protein C dysfunction mutations. <i>Pediatric Pulmonology</i> , 2021, 56, 2223-2231.	1.0	10
329	Serum IGFBP-2 in systemic sclerosis as a prognostic factor of lung dysfunction. <i>Scientific Reports</i> , 2021, 11, 10882.	1.6	12
330	Connective Tissue Disease-Associated Pulmonary Arterial Hypertension in Southern Taiwan: A Single-Center 10-Year Longitudinal Observation Cohort. <i>Healthcare (Switzerland)</i> , 2021, 9, 615.	1.0	4
331	New risk model is able to identify patients with a low risk of progression in systemic sclerosis. <i>RMD Open</i> , 2021, 7, e001524.	1.8	3
332	The safety of nintedanib for the treatment of interstitial lung disease: A systematic review and meta-analysis of randomized controlled trials. <i>PLoS ONE</i> , 2021, 16, e0251636.	1.1	13
333	Rational repurposing of tocilizumab for treatment of lung fibrosis in systemic sclerosis. <i>Lancet Rheumatology, The</i> , 2021, 3, e321-e323.	2.2	1
334	Pirfenidone in patients with progressive fibrotic interstitial lung diseases other than idiopathic pulmonary fibrosis (RELIEF): a double-blind, randomised, placebo-controlled, phase 2b trial. <i>Lancet Respiratory Medicine, the</i> , 2021, 9, 476-486.	5.2	254
335	SnapshotDx Quiz: June 2021. <i>Journal of Investigative Dermatology</i> , 2021, 141, e65-e70.	0.3	0
336	Cardiopulmonary exercise testing and prognosis in patients with systemic sclerosis without baseline pulmonary hypertension: a prospective cohort study. <i>Rheumatology International</i> , 2022, 42, 303-309.	1.5	5

#	ARTICLE	IF	CITATIONS
338	Detection and Early Referral of Patients With Interstitial Lung Abnormalities. <i>Chest</i> , 2022, 161, 470-482.	0.4	26
339	An update on targeted therapies in systemic sclerosis based on a systematic review from the last 3&#x2013;years. <i>Arthritis Research and Therapy</i> , 2021, 23, 155.	1.6	42
340	Interstitial Lung Disease in 2020. <i>Clinics in Chest Medicine</i> , 2021, 42, 229-239.	0.8	8
341	Reply. <i>Arthritis and Rheumatology</i> , 2021, 73, 2354-2355.	2.9	1
342	Interstitial Lung Disease in Connective Tissue Disease: A Common Lesion With Heterogeneous Mechanisms and Treatment Considerations. <i>Frontiers in Immunology</i> , 2021, 12, 684699.	2.2	39
343	Prevalence and Incidence of Chronic Fibrosing Interstitial Lung Diseases with a Progressive Phenotype in the United States Estimated in a Large Claims Database Analysis. <i>Advances in Therapy</i> , 2021, 38, 4100-4114.	1.3	23
344	Inhibition of Hsp90 Counteracts the Established Experimental Dermal Fibrosis Induced by Bleomycin. <i>Biomedicines</i> , 2021, 9, 650.	1.4	5
345	Rituximab as a Treatment Option after Autologous Hematopoietic Stem Cell Transplantation in a Patient with Systemic Sclerosis. <i>Journal of Personalized Medicine</i> , 2021, 11, 600.	1.1	4
346	Diagnosis and Management of Fibrotic Interstitial Lung Diseases. <i>Clinics in Chest Medicine</i> , 2021, 42, 321-335.	0.8	7
347	Inhaled treprostinil and forced vital capacity in patients with interstitial lung disease and associated pulmonary hypertension: a post-hoc analysis of the INCREASE study. <i>Lancet Respiratory Medicine</i> , 2021, 9, 1266-1274.	5.2	62
348	Disease Behaviour During the Peri-Diagnostic Period in Patients with Suspected Interstitial Lung Disease: The STARLINER Study. <i>Advances in Therapy</i> , 2021, 38, 4040-4056.	1.3	6
349	The challenge of diagnosing interstitial lung disease by HRCT: state of the art and future perspectives. <i>Jornal Brasileiro De Pneumologia</i> , 2021, 47, e20210199.	0.4	1
350	Management of Connective Tissue Disease-Associated Interstitial Lung Disease. <i>Clinics in Chest Medicine</i> , 2021, 42, 295-310.	0.8	8
351	Clinical and Methodologic Considerations With Regard to a Trial of Nintedanib in Patients With Systemic Sclerosis&#x2013;Associated Interstitial Lung Disease: Comment on the Reanalysis by Maher et al. <i>Arthritis and Rheumatology</i> , 2021, 73, 2353-2354.	2.9	0
352	Antifibrotic drugs in lung transplantation and chronic lung allograft dysfunction: a review. <i>European Respiratory Review</i> , 2021, 30, 210050.	3.0	8
353	Safety and efficacy of faecal microbiota transplantation by Anaerobic Cultivated Human Intestinal Microbiome (ACHIM) in patients with systemic sclerosis: study protocol for the randomised controlled phase II ReSScure trial. <i>BMJ Open</i> , 2021, 11, e048541.	0.8	7
355	Idiopathic pulmonary fibrosis and systemic sclerosis: pathogenic mechanisms and therapeutic interventions. <i>Cellular and Molecular Life Sciences</i> , 2021, 78, 5527-5542.	2.4	22
356	Myofibroblast fate plasticity in tissue repair and fibrosis: Deactivation, apoptosis, senescence and reprogramming. <i>Wound Repair and Regeneration</i> , 2021, 29, 678-691.	1.5	20

#	ARTICLE	IF	CITATIONS
357	Expert Perspective: Management of Refractory Inflammatory Myopathy. <i>Arthritis and Rheumatology</i> , 2021, 73, 1394-1407.	2.9	5
358	Clinical Significance of Interstitial Lung Disease and Its Acute Exacerbation in Microscopic Polyangiitis. <i>Chest</i> , 2021, 159, 2334-2345.	0.4	18
359	French recommendations for the management of systemic sclerosis. <i>Orphanet Journal of Rare Diseases</i> , 2021, 16, 322.	1.2	37
360	Chronic fibrosing progressing interstitial lung disease: a decision of Multidisciplinary Expert Board. <i>Pulmonologiya</i> , 2021, 31, 505-510.	0.2	5
361	Esophageal Dilation and Other Clinical Factors Associated With Pulmonary Function Decline in Patients With Systemic Sclerosis. <i>Journal of Rheumatology</i> , 2021, 48, 1830-1838.	1.0	4
363	Safety and efficacy of rituximab in systemic sclerosis (DESIREs): a double-blind, investigator-initiated, randomised, placebo-controlled trial. <i>Lancet Rheumatology</i> , The, 2021, 3, e489-e497.	2.2	105
364	Systemic Sclerosis-associated Interstitial Lung Disease: How to Incorporate Two Food and Drug Administration-approved Therapies in Clinical Practice. <i>Arthritis and Rheumatology</i> , 2022, 74, 13-27.	2.9	71
365	Exposure-safety analyses of nintedanib in patients with chronic fibrosing interstitial lung disease. <i>BMC Pulmonary Medicine</i> , 2021, 21, 244.	0.8	9
366	Rituximab for the treatment of systemic sclerosis: urgent need for an international randomised controlled trial. <i>Lancet Rheumatology</i> , The, 2021, 3, e463-e465.	2.2	4
367	Fractional analysis of bronchoalveolar lavage in systemic sclerosis-associated interstitial lung disease. <i>Journal of Thoracic Disease</i> , 2021, 13, 4146-4155.	0.6	7
368	Management and support of patients with fibrosing interstitial lung diseases. <i>Nurse Practitioner</i> , 2021, 46, 39-44.	0.2	2
369	Extracellular matrix and Hippo signaling as therapeutic targets of antifibrotic compounds for uterine fibroids. <i>Clinical and Translational Medicine</i> , 2021, 11, e475.	1.7	27
370	Efficacy and safety of nintedanib for pulmonary fibrosis in severe pneumonia induced by COVID-19: An interventional study. <i>International Journal of Infectious Diseases</i> , 2021, 108, 454-460.	1.5	65
371	Switching antifibrotics in patients with idiopathic pulmonary fibrosis: a multi-center retrospective cohort study. <i>BMC Pulmonary Medicine</i> , 2021, 21, 221.	0.8	15
372	Patient-centered Outcomes Research in Interstitial Lung Disease: An Official American Thoracic Society Research Statement. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2021, 204, e3-e23.	2.5	41
373	Characteristics and evaluation of acute exacerbations in chronic interstitial lung diseases. <i>Respiratory Medicine</i> , 2021, 183, 106400.	1.3	6
374	An update on interstitial lung disease. <i>British Journal of Hospital Medicine</i> (London, England: 2005), 2021, 82, 1-14.	0.2	2
375	Systemic Sclerosis Associated Interstitial Lung Disease and Nintedanib: A Rare Disease and a Promising Drug. <i>Cureus</i> , 2021, 13, e16404.	0.2	1

#	ARTICLE	IF	CITATIONS
376	Extracellular Heat Shock Proteins as Therapeutic Targets and Biomarkers in Fibrosing Interstitial Lung Diseases. <i>International Journal of Molecular Sciences</i> , 2021, 22, 9316.	1.8	11
377	Outcome measurement instrument selection for lung physiology in systemic sclerosis associated interstitial lung disease: A systematic review using the OMERACT filter 2.1 process. <i>Seminars in Arthritis and Rheumatism</i> , 2021, , .	1.6	3
378	Lung transplantation for interstitial lung disease. <i>European Respiratory Review</i> , 2021, 30, 210017.	3.0	36
379	Pharmacological Interactions of Nintedanib and Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis in Times of COVID-19 Pandemic. <i>Pharmaceutics</i> , 2021, 14, 819.	1.7	12
380	Epidemiology, Mortality and Healthcare Resource Utilization Associated With Systemic Sclerosis-Associated Interstitial Lung Disease in France. <i>Frontiers in Medicine</i> , 2021, 8, 699532.	1.2	5
381	Long COVID-19 Pulmonary Sequelae and Management Considerations. <i>Journal of Personalized Medicine</i> , 2021, 11, 838.	1.1	36
382	The role of lung ultrasound B-lines and serum KL-6 in the screening and follow-up of rheumatoid arthritis patients for an identification of interstitial lung disease: review of the literature, proposal for a preliminary algorithm, and clinical application to cases. <i>Arthritis Research and Therapy</i> , 2021, 23, 212.	1.6	16
383	SÃndrome de SjÃngren y afectaciÃ³n pulmonar. <i>Medicina ClÃnica</i> , 2022, 158, 181-185.	0.3	4
385	Inspiratory muscle training in interstitial lung disease: a systematic scoping review. <i>Jornal Brasileiro De Pneumologia</i> , 2021, 47, e20210089.	0.4	6
386	Integrative analysis of lung molecular signatures reveals key drivers of systemic sclerosis-associated interstitial lung disease. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 108-116.	0.5	16
387	Nintedanib downregulates the transition of cultured systemic sclerosis fibrocytes into myofibroblasts and their pro-fibrotic activity. <i>Arthritis Research and Therapy</i> , 2021, 23, 205.	1.6	10
390	Promise and challenge of systemic sclerosis therapies. <i>Nature Reviews Rheumatology</i> , 2021, 17, 581-582.	3.5	2
391	Mangostanin Derivatives as Novel and Orally Active Phosphodiesterase 4 Inhibitors for the Treatment of Idiopathic Pulmonary Fibrosis with Improved Safety. <i>Journal of Medicinal Chemistry</i> , 2021, 64, 13736-13751.	2.9	12
392	Safety and Effectiveness of Mycophenolate Mofetil in Interstitial Lung Diseases: Insights from a Machine Learning Radiographic Model. <i>Respiration</i> , 2022, 101, 262-271.	1.2	8
393	Nintedanib in progressive interstitial lung diseases: data from the whole INBUILD trial. <i>European Respiratory Journal</i> , 2022, 59, 2004538.	3.1	47
394	Efficacy and safety of biological drugs in interstitial lung disease associated with connective tissue diseases. <i>Expert Opinion on Drug Safety</i> , 2022, 21, 311-333.	1.0	1
395	Updates in Systemic Sclerosis Treatment and Applicability to Pediatric Scleroderma. <i>Rheumatic Disease Clinics of North America</i> , 2021, 47, 757-780.	0.8	5
398	Progressive Fibrosing Interstitial Lung Diseases: A Current Perspective. <i>Biomedicines</i> , 2021, 9, 1237.	1.4	10

#	ARTICLE	IF	CITATIONS
399	Nintedanib, a multitarget tyrosine kinase inhibitor, suppresses postoperative peritoneal adhesion formation in a rat model. <i>Surgery</i> , 2021, 170, 806-812.	1.0	1
400	Review for best practice in clinical rheumatology juvenile systemic sclerosis â€œ Updates and practice points. <i>Best Practice and Research in Clinical Rheumatology</i> , 2021, 35, 101688.	1.4	6
401	Early diagnosis of fibrotic interstitial lung disease: challenges and opportunities. <i>Lancet Respiratory Medicine</i> , 2021, 9, 1065-1076.	5.2	55
402	Pharmacologic Treatment of Anti-MDA5 Rapidly Progressive Interstitial Lung Disease. <i>Current Treatment Options in Rheumatology</i> , 2021, 7, 319-333.	0.6	17
403	Nailfold capillaroscopy by smartphone-dermatoscope for connective tissue disease diagnosis in interstitial lung disease: a prospective observational study. <i>ERJ Open Research</i> , 2021, 7, 00416-2021.	1.1	2
404	SSC-ILD mouse model induced by osmotic minipump delivered bleomycin: effect of Nintedanib. <i>Scientific Reports</i> , 2021, 11, 18513.	1.6	7
405	Therapeutic targets in lung tissue remodelling and fibrosis. , 2021, 225, 107839.		98
407	Combined assessment of the GAP index and body mass index at antifibrotic therapy initiation for prognosis of idiopathic pulmonary fibrosis. <i>Scientific Reports</i> , 2021, 11, 18579.	1.6	4
408	Contribution of monocytes and macrophages to the pathogenesis of systemic sclerosis: recent insights and therapeutic implications. <i>Current Opinion in Rheumatology</i> , 2021, 33, 463-470.	2.0	35
409	Therapeutic Approaches to Systemic Sclerosis: Recent Approvals and Future Candidate Therapies. <i>Clinical Reviews in Allergy and Immunology</i> , 2023, 64, 239-261.	2.9	20
410	An IPF-like disease course in disorders other than IPF: how can this be anticipated, recognized, and managed?. <i>Expert Review of Clinical Immunology</i> , 2021, 17, 1091-1101.	1.3	4
411	Nintedanib in Patients With Systemic Sclerosisâ€œAssociated Interstitial Lung Disease: Subgroup Analyses by Autoantibody Status and Modified Rodnan Skin Thickness Score. <i>Arthritis and Rheumatology</i> , 2022, 74, 518-526.	2.9	21
413	Antifibrotics in systemic sclerosis. <i>Best Practice and Research in Clinical Rheumatology</i> , 2021, 35, 101671.	1.4	4
414	Development of antifibrotic therapy for stricturing Crohnâ€™s disease: lessons from randomized trials in other fibrotic diseases. <i>Physiological Reviews</i> , 2022, 102, 605-652.	13.1	31
415	Treatment of fibrotic interstitial lung disease: current approaches and future directions. <i>Lancet</i> , The, 2021, 398, 1450-1460.	6.3	47
416	Is There a Place for Chimeric Antigen Receptorâ€œT Cells in the Treatment of Chronic Autoimmune Rheumatic Diseases?. <i>Arthritis and Rheumatology</i> , 2021, 73, 1954-1965.	2.9	28
417	Acute hospitalization in a cohort of patients with systemic sclerosis: a 10-year retrospective cohort study. <i>Rheumatology International</i> , 2021, , 1.	1.5	3
419	Aspectos claves de la NeumologÃa y la CirugÃa TorÃcica sometidos a debate en la era COVID-19. <i>Open Respiratory Archives</i> , 2021, 3, 100123.	0.0	0

#	ARTICLE	IF	CITATIONS
420	Hyperpolarized <sup>129</sup> Xe MRI and Spectroscopy of Gas-Exchange Abnormalities in Nonspecific Interstitial Pneumonia. <i>Radiology</i> , 2021, 301, 211-220.	3.6	11
421	An update on recent randomized clinical trials in systemic sclerosis. <i>Joint Bone Spine</i> , 2021, 88, 105184.	0.8	2
422	2020 guide for the diagnosis and treatment of interstitial lung disease associated with connective tissue disease. <i>Respiratory Investigation</i> , 2021, 59, 709-740.	0.9	45
423	Efficacy and safety of nintedanib in Japanese patients with progressive fibrosing interstitial lung diseases: Subgroup analysis of the randomised, double-blind, placebo-controlled, phase 3 INBUILD trial. <i>Respiratory Medicine</i> , 2021, 187, 106574.	1.3	6
424	The Role of Surgical Lung Biopsy in the Diagnosis of Fibrotic Interstitial Lung Disease: Perspective from the Pulmonary Fibrosis Foundation. <i>Annals of the American Thoracic Society</i> , 2021, 18, 1601-1609.	1.5	8
425	Adaptive Immunity in Interstitial Lung Disease. , 2022, , 144-157.		0
426	Scleroderma Associated Interstitial Lung Disease. , 2022, , 319-325.		0
427	Palliative Care in Interstitial Lung Disease. <i>Respiratory Medicine</i> , 2021, , 189-207.	0.1	0
428	Phase three clinical trials in idiopathic pulmonary fibrosis. <i>Expert Opinion on Orphan Drugs</i> , 2021, 9, 1-11.	0.5	2
429	Systemic Sclerosis: Current State and Survival After Lung Transplantation. <i>Cureus</i> , 2021, 13, e12797.	0.2	1
430	Systemic Sclerosis and Pulmonary Disease. <i>Advances in Experimental Medicine and Biology</i> , 2021, 1303, 173-182.	0.8	4
431	Chronic Fibrosing Interstitial Lung Disease with Progressive Phenotype. <i>Nauchno-Prakticheskaya Revmatologiya</i> , 2021, 58, 631-636.	0.2	3
432	Erfolgreiche Behandlung einer schweren interstitiellen Pneumonie durch Entfernung zirkulierender Autoantikörper: eine Fallserie. <i>Karger Kompass Pneumologie</i> , 2021, , 96-101.	0.0	0
433	Antifibrotic drugs in connective tissue disease-related interstitial lung disease (CTD-ILD): from mechanistic insights to therapeutic applications. <i>Drugs in Context</i> , 2021, 10, 1-13.	1.0	5
434	Spontaneous pneumothorax during nintedanib therapy in patients with systemic sclerosis-associated interstitial lung disease. <i>Respirology Case Reports</i> , 2021, 9, e00716.	0.3	3
435	Role of autoantibodies in the diagnosis and prognosis of interstitial lung disease in autoimmune rheumatic disorders. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2021, 13, 1759720X2110324.	1.2	30
436	Acute motor neuropathy with quadriparesis following treatment with triple tyrosine kinase inhibitor, nintedanib. <i>Respiratory Medicine Case Reports</i> , 2021, 34, 101472.	0.2	2
437	Targeting the $\alpha$ v Integrins in Fibroproliferative Disease. <i>RSC Drug Discovery Series</i> , 2020, , 37-75.	0.2	1

#	ARTICLE	IF	CITATIONS
438	Pamrevlumab for the treatment of idiopathic pulmonary fibrosis. Expert Opinion on Investigational Drugs, 2020, 29, 771-777.	1.9	40
440	Treatment with antifibrotic agents in idiopathic pleuroparenchymal fibroelastosis with usual interstitial pneumonia. ERJ Open Research, 2021, 7, 00196-2020.	1.1	10
441	Progression of fibrosing interstitial lung disease. Respiratory Research, 2020, 21, 32.	1.4	94
442	The resolution of the Expert Council on Interstitial Lung Diseases in Systemic Scleroderma (Moscow,) Tj ETQq1 1 0.784314 rgBT /Ove	0.1	8
443	lacta Alea Est: The Inexorable Advance of Tofacitinib in the Treatment of Dermatomyositis-Associated Rapidly Progressive Interstitial Lung Disease. A Case Report. Frontiers in Pharmacology, 2020, 11, 585761.	1.6	6
444	Patients with interstitial lung disease and pulmonary sarcoidosis are at high risk for severe illness related to COVID-19. Cleveland Clinic Journal of Medicine, 2020, , .	0.6	25
445	New Era of Management Concept on Pulmonary Fibrosis with Revisiting Framework of Interstitial Lung Diseases. Tuberculosis and Respiratory Diseases, 2020, 83, 195-200.	0.7	2
446	Recent Advances in Predicting Mortality and Progression of Systemic Sclerosisâ€™Associated Interstitial Lung Disease. Tuberculosis and Respiratory Diseases, 2020, 83, 326-328.	0.7	1
447	Practice guidelines for interstitial lung diseases: Widening the reach. Lung India, 2020, 37, 289.	0.3	1
448	Pharmacological treatment of pulmonary fibrosis. Journal of the Korean Medical Association, 2020, 63, 47.	0.1	4
449	News and failures from recent treatment trials in systemic sclerosis. European Journal of Rheumatology, 2020, 7, 242.	1.3	7
451	Management of Progressive Fibrosing Interstitial Lung Diseases (PF-ILD). Frontiers in Medicine, 2021, 8, 743977.	1.2	11
452	Nintedanib in the treatment of systemic rheumatic disease-associated interstitial lung disease. Vnitрни Lekarstvi, 2021, 67, 330-333.	0.1	0
454	Nintedanib in idiopathic and secondary pleuroparenchymal fibroelastosis. Orphanet Journal of Rare Diseases, 2021, 16, 419.	1.2	20
455	Revue des rÃ©cents essais randomisÃ©s dans la sclÃ©rodermie systÃ©mique. Revue Du Rhumatisme (Edition) Tj ETQq0 0 0 rgBT /Ove	0.0	0
457	Dysregulation of Type I Interferon Signaling in Systemic Sclerosis: a Promising Therapeutic Target?. Current Treatment Options in Rheumatology, 2021, 7, 349-360.	0.6	9
458	A Machine Learning Application to Predict Early Lung Involvement in Scleroderma: A Feasibility Evaluation. Diagnostics, 2021, 11, 1880.	1.3	14
459	Health Related Quality of Life in Interstitial Lung Disease: Can We Use the Same Concepts Around the World?. Frontiers in Medicine, 2021, 8, 745908.	1.2	2



#	ARTICLE	IF	CITATIONS
460	A Drug-Drug Interaction Study to Investigate the Effect of Nintedanib on the Pharmacokinetics of Microgynon (Ethinylestradiol and Levonorgestrel) in Female Patients with Systemic Sclerosis-Associated Interstitial Lung Disease. <i>European Journal of Drug Metabolism and Pharmacokinetics</i> , 2022, 47, 81-89.	0.6	3
461	Commonalities Between ARDS, Pulmonary Fibrosis and COVID-19: The Potential of Autotaxin as a Therapeutic Target. <i>Frontiers in Immunology</i> , 2021, 12, 687397.	2.2	22
462	Management of patients with fibrosing interstitial lung diseases. <i>American Journal of Health-System Pharmacy</i> , 2022, 79, 129-139.	0.5	6
464	Idiopathic pulmonary fibrosis: accurate diagnosis and early treatment. <i>Jornal Brasileiro De Pneumologia</i> , 2019, 45, e20190353.	0.4	0
466	Quels traitements pour les pneumopathies interstitielles diffuses associées aux sclérodermies systémiques ?. <i>Revue Des Maladies Respiratoires Actualites</i> , 2019, 11, 87-91.	0.0	0
467	Pulmonary involvement in systemic sclerosis. , 2019, , 90-105.		0
468	Quoi de neuf en médecine interne ?. <i>Annales De Dermatologie Et De Venereologie</i> , 2019, 146, 12S24-12S31.	0.5	0
469	Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease. <i>Journal of Visualized Experiments</i> , 2020, , .	0.2	9
470	Diagnosis and Treatment of Diffuse Connective Tissue Diseases. <i>The Japanese Journal of Rehabilitation Medicine</i> , 2020, 57, 686-692.	0.0	0
471	Clinical Relevance of the Serial Measurement of Krebs von den Lungen-6 Levels in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease. <i>Diagnostics</i> , 2021, 11, 2007.	1.3	6
472	Pharmacological treatments for SSc-ILD: Systematic review and critical appraisal of the evidence. <i>Autoimmunity Reviews</i> , 2021, 20, 102978.	2.5	17
473	Heart Failure with Preserved Ejection Fraction and Cardiomyopathy: an Under-recognized Complication of Systemic Sclerosis. <i>Current Treatment Options in Cardiovascular Medicine</i> , 2021, 23, 1.	0.4	0
474	Treatment of systemic sclerosis. <i>Presse Medicale</i> , 2021, 50, 104088.	0.8	10
476	Pathological Insight into 5-HT2B Receptor Activation in Fibrosing Interstitial Lung Diseases. <i>International Journal of Molecular Sciences</i> , 2021, 22, 225.	1.8	14
477	Collaboration between patient organisations and a clinical research sponsor in a rare disease condition: learnings from a community advisory board and best practice for future collaborations. <i>BMJ Open</i> , 2020, 10, e039473.	0.8	12
478	Compromiso intersticial pulmonar en la esclerosis sistémica. <i>Revista Colombiana De Reumatología</i> , 2020, 27, 36-43.	0.0	0
480	Diarrhoea in systemic sclerosis patients as a nocebo effect of nintedanib. <i>European Respiratory Journal</i> , 2021, 57, 2003021.	3.1	3
481	Rheumatoid Arthritis Interstitial Lung Disease: Measuring and Predictive Factors Among Patients Treated in Rehabilitation Clinics at Royal Medical Services. <i>Medicinski Arhiv = Medical Archives = Archives De Médecine</i> , 2020, 74, 450.	0.4	2

#	ARTICLE	IF	CITATIONS
483	Systemic Sclerosis in the Elderly. , 2020, , 207-228.		0
484	Pharmacological treatment of idiopathic pulmonary fibrosis: time to step out of the comfort zone?. Jornal Brasileiro De Pneumologia, 2020, 46, e20200193-e20200193.	0.4	0
485	Nintedanibâ€”A Potential New Therapy for Systemic Sclerosis-associated Interstitial Lung Disease. US Respiratory & Pulmonary Diseases, 2020, 5, 28.	0.2	0
486	Interstitial lung involvement in systemic sclerosis. Revista Colombiana De ReumatologÃa (English) Tj ETQq1 1 0.784314 rgBT /Overlo 0,1	0.1	0
487	Interstitial Lung Disease in Connective Tissue Diseases: Survival Patterns in a Population-Based Cohort. Journal of Clinical Medicine, 2021, 10, 4830.	1.0	14
489	Nintedanib in treating interstitial lung disease associated with systemic scleroderma. Klinicka Farmakologie A Farmacie, 2021, 35, 80-86.	0.1	0
490	Lung function trajectory in progressive fibrosing interstitial lung disease. European Respiratory Journal, 2022, 59, 2101396.	3.1	40
491	Systemic Sclerosis. European Medical Journal Rheumatology, 0, , 100-109.	0.0	4
492	Ways to improve the diagnosis and treatment of interstitial lung disease associated with systemic sclerosis in the Siberian Federal District (materials of the advisory board of rheumatologists and) Tj ETQq0 0 0 rgBT /Overlock10 Tf 50 4	0.0	0
493	Treatment of Systemic Sclerosis Associated Interstitial Lung Disease. Journal of Clinical Rheumatology and Immunology, 2020, 20, 56-64.	0.4	1
494	Current therapy of interstitial pneumonia associated with systemic scleroderma. Nauchno-Prakticheskaya Revmatologiya, 2020, 58, 520-531.	0.2	4
495	Management of interstitial lung diseases: A consensus statement of the Indian Chest Society (ICS) and National College of Chest Physicians (NCCP). Lung India, 2020, 37, 359-378.	0.3	2
496	Treatment of systemic sclerosis associated ILD: Lessons from clinical trials. Journal of Scleroderma and Related Disorders, 2020, 5, 61-71.	1.0	14
497	Kinetic changes in serum KL-6 levels predict disease progression in patients with systemic sclerosis-associated interstitial lung disease. Respiratory Medicine, 2022, 191, 106689.	1.3	7
498	Delivery of pDNA to the Lung by Lipopolyplexes Using N-Lauroylsarcosine and Effect on the Pulmonary Fibrosis. Pharmaceutics, 2021, 13, 1983.	2.0	4
499	Emerging therapeutic targets for idiopathic pulmonary fibrosis: preclinical progress and therapeutic implications. Expert Opinion on Therapeutic Targets, 2021, 25, 939-948.	1.5	6
500	Use of Mycophenolate Mofetil for Systemic Sclerosis and Systemic Sclerosis-Associated Interstitial Lung Disease: Information from a Japanese Hospital Claims Database. Modern Rheumatology, 2021, , .	0.9	1
501	Baseline characteristics of systemic sclerosis patients with restrictive lung disease in a multiâ€”center USâ€”based longitudinal registry. International Journal of Rheumatic Diseases, 2022, 25, 163-174.	0.9	3

#	ARTICLE	IF	CITATIONS
502	Journal Club: Efficacy of Tocilizumab in Early Systemic Sclerosis-Related Interstitial Lung Disease. <i>ACR Open Rheumatology</i> , 2022, 4, 119-122.	0.9	1
503	Collagen 1a1 Expression by Airway Macrophages Increases In Fibrotic ILDs and Is Associated With FVC Decline and Increased Mortality. <i>Frontiers in Immunology</i> , 2021, 12, 645548.	2.2	17
504	PD-L1 Expression in Patients with Idiopathic Pulmonary Fibrosis. <i>Journal of Clinical Medicine</i> , 2021, 10, 5562.	1.0	13
505	TELO-SCOPE study: a randomised, double-blind, placebo-controlled, phase 2 trial of danazol for short telomere related pulmonary fibrosis. <i>BMJ Open Respiratory Research</i> , 2021, 8, e001127.	1.2	13
507	Long-Term Safety and Efficacy of Tocilizumab in Early Systemic Sclerosis-Related Interstitial Lung Disease: Open-Label Extension of a Phase 3 Randomized Controlled Trial. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2022, 205, 674-684.	2.5	57
508	Progression of patients with Raynaud's phenomenon to systemic sclerosis: a five-year analysis of the European Scleroderma Trial and Research group multicentre, longitudinal registry study for Very Early Diagnosis of Systemic Sclerosis (VEDOSS). <i>Lancet Rheumatology</i> , The, 2021, 3, e834-e843.	2.2	42
509	Mortality Trends in Rheumatoid Arthritis: Zooming in on Interstitial Lung Disease. <i>Annals of the American Thoracic Society</i> , 2021, 18, 1953-1954.	1.5	4
510	Management of interstitial lung diseases: A consensus statement of the Indian Chest Society (ICS) and National College of Chest Physicians (NCCP). <i>Lung India</i> , 2020, 37, 359.	0.3	9
511	Addition of antifibrotic therapy to immunosuppression in hypersensitivity pneumonitis: A case series. <i>Respiratory Medicine Case Reports</i> , 2021, 34, 101562.	0.2	2
512	Role of antifibrotics in the management of idiopathic inflammatory myopathy associated interstitial lung disease. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2021, 13, 1759720X2110609.	1.2	7
513	The Cutting-edge of the Diagnosis and Management of Interstitial Lung Disease. <i>The Journal of the Japanese Society of Internal Medicine</i> , 2021, 110, 124-132.	0.0	0
514	Impact of Concomitant Medication Burden on Tolerability of Disease-targeted Therapy and Survival in Interstitial Lung Disease. <i>Annals of the American Thoracic Society</i> , 2022, 19, 962-970.	1.5	5
515	Impact of lung function decline on time to hospitalisation events in systemic sclerosis-associated interstitial lung disease (SSc-ILD): a joint model analysis. <i>Arthritis Research and Therapy</i> , 2022, 24, 19.	1.6	8
516	Methotrexate and The Lung in Rheumatoid Arthritis. <i>European Medical Journal Rheumatology</i> , 0, , 80-90.	0.0	1
517	6. Interstitial Pneumonias: Update in the Diagnosis and Treatment. <i>The Journal of the Japanese Society of Internal Medicine</i> , 2020, 109, 1899-1905.	0.0	0
518	Interstitial Pneumonia with Autoimmune Features. <i>Journal of the Royal College of Physicians of Edinburgh</i> , The, 2020, 50, 247-255.	0.2	1
519	Combination Therapy with Rituximab, Tofacitinib and Pirfenidone in a Patient with Rapid Progressive Interstitial Lung Disease (RP-ILD) Due to MDA5 Antibody-Associated Dermatomyositis: A Case Report. <i>Medicina (Lithuania)</i> , 2021, 57, 1358.	0.8	11
520	Increased Red Blood Cell Distribution Width in the First Year after Diagnosis Predicts Worsening of Systemic Sclerosis-Associated Interstitial Lung Disease at 5 Years: A Pilot Study. <i>Diagnostics</i> , 2021, 11, 2274.	1.3	2

#	ARTICLE	IF	CITATIONS
521	Choosing pharmacotherapy for ILD in patients with connective tissue disease. <i>Breathe</i> , 2021, 17, 210114.	0.6	1
522	The Effect of Anti-CCP Antibody Determination Method on Its Predictive Significance for Interstitial Lung Disease Progression in Systemic Sclerosis. <i>ACR Open Rheumatology</i> , 2022, 4, 345-351.	0.9	12
524	Dysregulation of the gene signature of effector regulatory T cells in the early phase of systemic sclerosis. <i>Rheumatology</i> , 2022, , .	0.9	3
525	Thoracic lymphadenopathies in diffuse systemic sclerosis: an observational study on 48 patients using computed tomography. <i>BMC Pulmonary Medicine</i> , 2022, 22, 44.	0.8	2
529	Immunosuppressive Therapy After Autologous Hematopoietic Stem Cell Transplantation in Systemic Sclerosis Patients—High Efficacy of Rituximab. <i>Frontiers in Immunology</i> , 2021, 12, 817893.	2.2	6
530	Domains and outcome measures for the assessment of limited cutaneous systemic sclerosis: an international collaborative scoping review. <i>Rheumatology</i> , 2022, 61, 3132-3148.	0.9	4
531	Systemic Sclerosis: From Pathophysiology to Novel Therapeutic Approaches. <i>Biomedicines</i> , 2022, 10, 163.	1.4	16
532	The role of antifibrotic therapies in the treatment of systemic sclerosis-associated interstitial lung disease. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2022, 14, 1759720X2110666.	1.2	0
533	Therapeutic Options for Systemic Sclerosis: Current and Future Perspectives in Tackling Immune-Mediated Fibrosis. <i>Biomedicines</i> , 2022, 10, 316.	1.4	8
534	Pulmonary involvement in Sjögren's syndrome. <i>Medicina Clínica (English Edition)</i> , 2022, 158, 181-181.	0.1	0
535	Reproductive Issues and Pregnancy Implications in Systemic Sclerosis. <i>Clinical Reviews in Allergy and Immunology</i> , 2023, 64, 321-342.	2.9	6
537	Tolerability of nintedanib in the elderly with idiopathic pulmonary fibrosis: A single-center retrospective study. <i>PLoS ONE</i> , 2022, 17, e0262795.	1.1	7
538	Systemic sclerosis in adults. Part II: management and therapeutics. <i>Journal of the American Academy of Dermatology</i> , 2022, 87, 957-978.	0.6	7
539	Dyspnoea and cough in patients with systemic sclerosis-associated interstitial lung disease in the SENSICIS trial. <i>Rheumatology</i> , 2022, 61, 4397-4408.	0.9	11
540	Myositis-associated interstitial lung disease: a comprehensive approach to diagnosis and management. <i>Clinical and Experimental Rheumatology</i> , 2021, , .	0.4	0
541	Interstitial pneumonia with autoimmune features. <i>Handbook of Systemic Autoimmune Diseases</i> , 2022, , 1-20.	0.1	0
542	The role of antifibrotics in the treatment of rheumatoid arthritis-associated interstitial lung disease. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2022, 14, 1759720X2210744.	1.2	7
543	Lung involvement in SLE. <i>Handbook of Systemic Autoimmune Diseases</i> , 2022, , 41-53.	0.1	0

#	ARTICLE	IF	CITATIONS
544	Inflammatory myopathy, mixed connective tissue disease, and antisynthetase syndrome. Handbook of Systemic Autoimmune Diseases, 2022, , 105-151.	0.1	0
545	Sjogren's syndrome and lung involvement. Handbook of Systemic Autoimmune Diseases, 2022, , 55-71.	0.1	0
546	Lung involvement in systemic sclerosis. Handbook of Systemic Autoimmune Diseases, 2022, , 73-103.	0.1	0
547	Nintedanib in Patients With Autoimmune Disease-Related Progressive Fibrosing Interstitial Lung Diseases: Subgroup Analysis of the <sc>INBUILD</sc> Trial. Arthritis and Rheumatology, 2022, 74, 1039-1047.	2.9	44
548	Usual interstitial pneumonia: a clinically significant pattern, but not the final word. Modern Pathology, 2022, 35, 589-593.	2.9	4
549	Emerging Evidence and Treatment Perspectives from Randomized Clinical Trials in Systemic Sclerosis: Focus on Interstitial Lung Disease. Biomedicines, 2022, 10, 504.	1.4	2
550	Peripheral blood gene expression profiling shows predictive significance for response to mycophenolate in systemic sclerosis-related interstitial lung disease. Annals of the Rheumatic Diseases, 2022, 81, 854-860.	0.5	13
551	Myositis-associated interstitial lung disease: a comprehensive approach to diagnosis and management. Clinical and Experimental Rheumatology, 2022, 40, 373-383.	0.4	18
552	Treatment and Systemic Sclerosis Interstitial Lung Disease Outcome: The Overweight Paradox. Biomedicines, 2022, 10, 434.	1.4	5
553	Future Treatment Options in Systemic Sclerosis-Potential Targets and Ongoing Clinical Trials. Journal of Clinical Medicine, 2022, 11, 1310.	1.0	9
555	Gastrointestinal symptom severity and progression in systemic sclerosis. Rheumatology, 2022, , .	0.9	2
556	Understanding and Therapeutically Targeting the Scleroderma Myofibroblast. Current Treatment Options in Rheumatology, 2022, 8, 1-18.	0.6	0
557	Pirfenidone exacerbates Th2-driven vasculopathy in a mouse model of systemic sclerosis-associated interstitial lung disease. European Respiratory Journal, 2022, 60, 2102347.	3.1	7
558	IL-33/regulatory T cell axis suppresses skin fibrosis. Journal of Investigative Dermatology, 2022, , .	0.3	4
559	Patient preferences for the treatment of systemic sclerosis-associated interstitial lung disease: a discrete choice experiment. Rheumatology, 2022, 61, 4035-4046.	0.9	6
560	Utility of phototherapy in patients with systemic sclerosis: Systematic review. Dermatologic Therapy, 2022, 35, e15478.	0.8	1
561	Skin involvement in early diffuse cutaneous systemic sclerosis: an unmet clinical need. Nature Reviews Rheumatology, 2022, 18, 276-285.	3.5	18
562	Plasma Metabolomic Profiling Reveals Four Possibly Disrupted Mechanisms in Systemic Sclerosis. Biomedicines, 2022, 10, 607.	1.4	9

#	ARTICLE	IF	CITATIONS
563	Responsiveness and meaningful change thresholds of the Living with Pulmonary Fibrosis (L-PF) questionnaire Dyspnoea and Cough scores in patients with progressive fibrosing interstitial lung diseases. <i>BMJ Open Respiratory Research</i> , 2022, 9, e001167.	1.2	6
564	Clinical Overview of Progressive Fibrotic Interstitial Lung Disease. <i>Frontiers in Medicine</i> , 2022, 9, 858339.	1.2	3
565	Novel Th17 Lymphocyte Populations, Th17.1 and PD1+Th17, are Increased in Takayasu Arteritis, and Both Th17 and Th17.1 Sub-Populations Associate with Active Disease. <i>Journal of Inflammation Research</i> , 2022, Volume 15, 1521-1541.	1.6	21
566	A Narrative Review of Pathogenetic and Histopathologic Aspects, Epidemiology, Classification Systems, and Disease Outcome Measures in Systemic Sclerosis. <i>Clinical Reviews in Allergy and Immunology</i> , 2023, 64, 358-377.	2.9	8
567	Thoracic Involvement in Systemic Autoimmune Rheumatic Diseases: Pathogenesis and Management. <i>Clinical Reviews in Allergy and Immunology</i> , 2022, 63, 472-489.	2.9	13
568	Primary heart involvement in systemic sclerosis, from conventional to innovative targeted therapeutic strategies. <i>Journal of Scleroderma and Related Disorders</i> , 2022, 7, 179-188.	1.0	3
569	PDGF/PDGFR: A Possible Molecular Target in Scleroderma Fibrosis. <i>International Journal of Molecular Sciences</i> , 2022, 23, 3904.	1.8	13
570	FocuSSced on the Target in Systemic Sclerosisâ€“Interstitial Lung Disease: Another Arrow in the Quiver?. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2022, 205, 608-610.	2.5	2
571	Chronic Dyspnea with Raynaud's Phenomenon and Elevated ANA: A Diagnosis of Systemic Sclerosis Sine Scleroderma. <i>American Journal of the Medical Sciences</i> , 2022, , .	0.4	1
572	Safety and tolerability of nintedanib in patients with progressive fibrosing interstitial lung diseases: data from the randomized controlled INBUILD trial. <i>Respiratory Research</i> , 2022, 23, 85.	1.4	17
573	Limited efficacy of nintedanib for idiopathic pleuroparenchymal fibroelastosis. <i>Respiratory Investigation</i> , 2022, 60, 562-569.	0.9	14
574	Interstitial pneumonia with autoimmune features: challenges and controversies. <i>European Respiratory Review</i> , 2021, 30, 210177.	3.0	16
575	Advances with pharmacotherapy for the treatment of interstitial lung disease. <i>Expert Opinion on Pharmacotherapy</i> , 2022, 23, 483-495.	0.9	0
576	Organ Manifestation and Systematic Organ Screening at the Onset of Inflammatory Rheumatic Diseases. <i>Diagnostics</i> , 2022, 12, 67.	1.3	2
577	Real-life prevalence of progressive fibrosing interstitial lung diseases. <i>Scientific Reports</i> , 2021, 11, 23988.	1.6	15
578	Efficacy of antifibrotic drugs, nintedanib and pirfenidone, in treatment of progressive pulmonary fibrosis in both idiopathic pulmonary fibrosis (IPF) and non-IPF: a systematic review and meta-analysis. <i>BMC Pulmonary Medicine</i> , 2021, 21, 411.	0.8	47
579	E4 engages uPAR and enolase-1 and activates urokinase to exert antifibrotic effects. <i>JCI Insight</i> , 2021, 6, .	2.3	12
580	Autoimmune Progressive Fibrosing Interstitial Lung Disease: Predictors of Fast Decline. <i>Frontiers in Pharmacology</i> , 2021, 12, 778649.	1.6	9

#	ARTICLE	IF	CITATIONS
581	Early Radiographic Progression of Scleroderma. <i>Chest</i> , 2022, 161, 1310-1319.	0.4	9
583	Pirfenidone in Unclassifiable Interstitial Lung Disease: A Subgroup Analysis by Concomitant Mycophenolate Mofetil and/or Previous Corticosteroid Use. <i>Advances in Therapy</i> , 2022, 39, 1081-1095.	1.3	6
584	Screening and management of subclinical interstitial lung disease in systemic sclerosis: an international survey. <i>Rheumatology</i> , 2022, 61, 3401-3407.	0.9	3
585	Pharmacological Management of Idiopathic Pulmonary Fibrosis. , 0, , .		0
586	Challenges in the Diagnosis and Management of Patients with Fibrosing Interstitial Lung Disease. Case Reports in Pulmonology, 2022, 2022, 1-7.	0.2	1
587	Autoimmunity in interstitial lung disease. , 2022, , 291-310.		0
588	Current perspective of progressive-fibrosing interstitial lung disease. <i>Respiratory Investigation</i> , 2022, 60, 503-509.	0.9	8
590	Systemic Sclerodermaâ€™ Definition, Clinical Picture and Laboratory Diagnostics. <i>Journal of Clinical Medicine</i> , 2022, 11, 2299.	1.0	15
591	Current advances in the treatment of systemic sclerosis. <i>Current Opinion in Pharmacology</i> , 2022, 64, 102211.	1.7	23
623	Computed Tomography of the Chest to Screen for Interstitial Lung Disease in Patients With Systemic Sclerosis at Expert Scleroderma Centers in the United States. <i>ACR Open Rheumatology</i> , 2022, 4, 596-602.	0.9	2
624	Comment on: Combination of immunosuppressive therapy and nintedanib improves capillaroscopic changes in systemic sclerosis-interstitial lung disease: a case report. Reply. <i>Rheumatology Advances in Practice</i> , 2022, 6, rkac025.	0.3	0
625	The pathogenesis and pathology of idiopathic pleuroparenchymal fibroelastosis. <i>Histology and Histopathology</i> , 2021, 36, 291-303.	0.5	4
626	Interstitielle Lungenerkrankungen. , 2022, , 92-102.		0
627	Anti-fibrotic effects of pharmacologic FGF-2: a review of recent literature. <i>Journal of Molecular Medicine</i> , 2022, 100, 847-860.	1.7	3
628	Autologous hematopoietic stem cell transplantation promotes connective tissue remodeling in systemic sclerosis patients. <i>Arthritis Research and Therapy</i> , 2022, 24, 95.	1.6	4
629	Chronic fibrosing interstitial lung diseases according to the register of Irkutsk (Russia). <i>Pulmonologiya</i> , 2022, 32, 199-207.	0.2	0
631	Detection and Monitoring of Interstitial Lung Disease in Patients with Systemic Sclerosis. <i>Current Rheumatology Reports</i> , 2022, 24, 166-173.	2.1	8
632	Impact of Lung Biopsy Information on Treatment Strategy of Patients with Interstitial Lung Diseases: The Glass Is Half Full. <i>Annals of the American Thoracic Society</i> , 2022, 19, 720-722.	1.5	1

#	ARTICLE	IF	CITATIONS
634	Impact of Sex and Gender on Autoimmune Lung Disease: Opportunities for Future Research: NHLBI Working Group Report. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2022, 206, 817-823.	2.5	3
635	Nintedanib in Progressive Pulmonary Fibrosis: A Systematic Review and Meta-Analysis. <i>Annals of the American Thoracic Society</i> , 2022, 19, 1040-1049.	1.5	24
636	Management of Connective Tissue Disease-related Interstitial Lung Disease. <i>Current Pulmonology Reports</i> , 2022, 11, 86-98.	0.5	11
637	Outpatient Pharmacologic Management of Lung Transplant Candidates on the Waiting List. <i>Thoracic Surgery Clinics</i> , 2022, 32, 111-119.	0.4	1
638	Chronic Lung Allograft Dysfunction. <i>Thoracic Surgery Clinics</i> , 2022, 32, 231-242.	0.4	8
639	Association between bevacizumab with cancer drug therapies and drug-induced interstitial lung disease in patients with solid tumor: A systematic review and meta-analysis of randomized clinical trials. <i>Critical Reviews in Oncology/Hematology</i> , 2022, 174, 103703.	2.0	2
640	The Latest in Animal Models of Pulmonary Hypertension and Right Ventricular Failure. <i>Circulation Research</i> , 2022, 130, 1466-1486.	2.0	35
641	Interstitial Lung Disease in Rheumatoid Arthritis: A Practical Review. <i>Frontiers in Medicine</i> , 2022, 9, .	1.2	14
642	Meta-Analysis of Effect of Nintedanib on Reducing FVC Decline Across Interstitial Lung Diseases. <i>Advances in Therapy</i> , 2022, 39, 3392-3402.	1.3	12
643	Calcineurin inhibitors in systemic sclerosis – a systematic literature review. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2022, 14, 1759720X2210923.	1.2	1
644	The Pathophysiological Roles of Regulatory T Cells in the Early Phase of Systemic Sclerosis. <i>Frontiers in Immunology</i> , 2022, 13, .	2.2	6
645	Impact of lung function and baseline clinical characteristics on patient-reported outcome measures in systemic sclerosis-associated interstitial lung disease. <i>Rheumatology</i> , 2023, 62, SI43-SI53.	0.9	6
646	Resistance to Gemcitabine in Pancreatic Ductal Adenocarcinoma: A Physiopathologic and Pharmacologic Review. <i>Cancers</i> , 2022, 14, 2486.	1.7	29
647	Liver Injury with Nintedanib: A Pharmacovigilance-Pharmacokinetic Appraisal. <i>Pharmaceuticals</i> , 2022, 15, 645.	1.7	5
648	Interstitial Pneumonia with Autoimmune Features: What the Rheumatologist Needs to Know. <i>Current Rheumatology Reports</i> , 0, , .	2.1	3
649	Use of Biologics for Systemic Sclerosis and Systemic Sclerosis-Associated Interstitial Lung Disease: Information from a Japanese Hospital Claims Database. <i>Modern Rheumatology</i> , 0, , .	0.9	1
650	Analyses of the Efficacy and Safety of Antifibrotic Therapies in Non-IPF Pulmonary Fibrosis, Progressing Despite Management. <i>Annals of the American Thoracic Society</i> , 2022, 19, 904-906.	1.5	0
651	Treatment approach to connective tissue disease-associated interstitial lung disease. <i>Current Opinion in Pharmacology</i> , 2022, 65, 102245.	1.7	6



#	ARTICLE	IF	CITATIONS
652	III. Interstitial Lung Disease. The Journal of the Japanese Society of Internal Medicine, 2021, 110, 1076-1084.	0.0	0
655	Antifibrotic therapy and its indications for interstitial pulmonary fibrosis. Vnitri Lekarstvi, 2022, 68, 212-215.	0.1	0
656	Pulmonary fibrosis associated with rheumatoid arthritis: from pathophysiology to treatment strategies. Expert Review of Respiratory Medicine, 2022, 16, 541-553.	1.0	11
657	Changes on chest HRCT in systemic sclerosis-related interstitial lung disease after autologous haematopoietic stem cell transplantation. Rheumatology, 2023, 62, S132-S142.	0.9	4
658	Interstitial lung disease in ANCA-associated vasculitis: associated factors, radiographic features and mortality. Rheumatology, 2023, 62, 716-725.	0.9	4
659	Rituximab treatment for systemic sclerosis-associated interstitial lung disease: a case series of 13 patients. Internal Medicine Journal, 2023, 53, 1147-1153.	0.5	3
660	Nintedanib induces gene expression changes in the lung of induced-rheumatoid arthritis-associated interstitial lung disease mice. PLoS ONE, 2022, 17, e0270056.	1.1	2
662	Discovery of Aryloxyphenyl-Heptapeptide Hybrids as Potent and Selective Matrix Metalloproteinase-2 Inhibitors for the Treatment of Idiopathic Pulmonary Fibrosis. Journal of Medicinal Chemistry, 2022, 65, 8493-8510.	2.9	9
663	Nintedanib vs pirfenidone in the management of COVID-19 lung fibrosis: A single-centre study. Journal of the Royal College of Physicians of Edinburgh, The, 2022, 52, 100-104.	0.2	13
664	JAK1/2 Inhibitor Baricitinib Improves Skin Fibrosis and Digital Ulcers in Systemic Sclerosis. Frontiers in Medicine, 0, 9, .	1.2	16
665	Pregnancy Considerations for Patients With Interstitial Lung Disease. Chest, 2022, 162, 1093-1105.	0.4	2
666	Kasugamycin Is a Novel Chitinase 1 Inhibitor with Strong Antifibrotic Effects on Pulmonary Fibrosis. American Journal of Respiratory Cell and Molecular Biology, 2022, 67, 309-319.	1.4	6
667	Advances in the management of idiopathic pulmonary fibrosis and progressive pulmonary fibrosis. BMJ, The, 0, , e066354.	3.0	14
668	Decline in forced vital capacity in subjects with systemic sclerosis-associated interstitial lung disease in the SENSICIS trial compared with healthy reference subjects. Respiratory Research, 2022, 23, .	1.4	1
669	Kidney Involvement in Systemic Sclerosis. Journal of Personalized Medicine, 2022, 12, 1123.	1.1	5
670	Effect of Nintedanib on Progression of Systemic Sclerosis-Associated Interstitial Lung Disease Over 100 Weeks: Data From a Randomized Controlled Trial. ACR Open Rheumatology, 2022, 4, 837-844.	0.9	8
671	Interstitial Lung Disease in ANCA-Associated Vasculitis: Pathogenic Considerations and Impact for Patients' Outcomes. Current Rheumatology Reports, 2022, 24, 259-267.	2.1	5
672	Assessment of disease outcome measures in systemic sclerosis. Nature Reviews Rheumatology, 2022, 18, 527-541.	3.5	10

#	ARTICLE	IF	CITATIONS
673	Macrophages as determinants and regulators of fibrosis in systemic sclerosis. <i>Rheumatology</i> , 2023, 62, 535-545.	0.9	11
674	Recent advances in the management of systemic sclerosis-associated interstitial lung disease. <i>Current Opinion in Pulmonary Medicine</i> , 2022, 28, 441-447.	1.2	6
675	Epigenetic Regulation of Profibrotic Macrophages in Systemic Sclerosis-associated Interstitial Lung Disease. <i>Arthritis and Rheumatology</i> , 2022, 74, 2003-2014.	2.9	12
676	<i>FLT3</i> functional low-frequency variant rs76428106-C is associated with susceptibility to systemic sclerosis. <i>Rheumatology</i> , 0, , .	0.9	0
677	Open questions on the management of targeted therapies for the treatment of systemic sclerosis-interstitial lung disease: results of a EUSTAR survey based on a systemic literature review. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2022, 14, 1759720X2211164.	1.2	7
678	Leveraging Therapy-Specific Polygenic Risk Scores to Predict Restrictive Lung Defects in Childhood Cancer Survivors. <i>Cancer Research</i> , 2022, 82, 2940-2950.	0.4	3
679	Management of progressive pulmonary fibrosis associated with connective tissue disease. <i>Expert Review of Respiratory Medicine</i> , 2022, 16, 765-774.	1.0	6
680	Reduced Cathepsin L expression and secretion into the extracellular milieu contribute to lung fibrosis in systemic sclerosis. <i>Rheumatology</i> , 2023, 62, 1306-1316.	0.9	6
681	Clinical significance of pulmonary hypertension in interstitial lung disease: A consensus statement from the Pulmonary Vascular Research Institute's innovative drug development initiative's Group 3 pulmonary hypertension. <i>Pulmonary Circulation</i> , 2022, 12, .	0.8	15
682	Nintedanib Inhibits Endothelial Mesenchymal Transition in Bleomycin-Induced Pulmonary Fibrosis via Focal Adhesion Kinase Activity Reduction. <i>International Journal of Molecular Sciences</i> , 2022, 23, 8193.	1.8	7
684	Antifibrotic therapy with nintedanib is beneficial for patients with negative prognostic factors. , 0, , .		0
685	Modern principles and prospects for drug therapy of interstitial lung diseases in children. <i>Rossiyskiy Vestnik Perinatologii i Pediatrii</i> , 2022, 67, 18-22.	0.1	1
686	Long-Term Efficacy and Low Adverse Events of Methylprednisolone Pulses Combined to Low-Dose Glucocorticoids for Systemic Sclerosis: A Retrospective Clinical Study of 10 Years' Follow-Up. <i>Journal of Inflammation Research</i> , 0, Volume 15, 4421-4433.	1.6	4
687	Towards Treatable Traits for Pulmonary Fibrosis. <i>Journal of Personalized Medicine</i> , 2022, 12, 1275.	1.1	2
688	Interstitial lung diseases. <i>Lancet</i> , The, 2022, 400, 769-786.	6.3	99
689	Effects of nintedanib on disease progression and safety in Japanese patients with progressive fibrosing interstitial lung diseases: Further subset analysis from the whole INBUILD trial. <i>Respiratory Investigation</i> , 2022, 60, 787-797.	0.9	3
690	New Era in Systemic Sclerosis Treatment: Recently Approved Therapeutics. <i>Journal of Clinical Medicine</i> , 2022, 11, 4631.	1.0	18
692	Understanding diagnostic pathways in systemic sclerosis and systemic sclerosis-associated interstitial lung disease: A retrospective cohort study. <i>Medicine (United States)</i> , 2022, 101, e29993.	0.4	3

#	ARTICLE	IF	CITATIONS
693	Continued treatment with nintedanib in patients with systemic sclerosis-associated interstitial lung disease: data from SENSIS-ON. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 1722-1729.	0.5	19
694	The Effectiveness of Nintedanib in Patients with Idiopathic Pulmonary Fibrosis, Familial Pulmonary Fibrosis and Progressive Fibrosing Interstitial Lung Diseases: A Real-World Study. <i>Biomedicines</i> , 2022, 10, 1973.	1.4	10
695	Epidemiology and real-life experience in progressive pulmonary fibrosis. <i>Current Opinion in Pulmonary Medicine</i> , 2022, 28, 407-413.	1.2	10
696	JAK inhibitors and systemic sclerosis: A systematic review of the literature. <i>Autoimmunity Reviews</i> , 2022, 21, 103168.	2.5	23
697	Let's talk about sex in interstitial lung disease. <i>Lancet Rheumatology</i> , The, 2022, 4, e648-e650.	2.2	0
698	Safety and tolerability of nintedanib in patients with interstitial lung diseases in subgroups by sex: a post-hoc analysis of pooled data from four randomised controlled trials. <i>Lancet Rheumatology</i> , The, 2022, 4, e679-e687.	2.2	7
699	Sex differences in clinical outcomes and biological profiles in systemic sclerosis-associated interstitial lung disease: a post-hoc analysis of two randomised controlled trials. <i>Lancet Rheumatology</i> , The, 2022, 4, e668-e678.	2.2	8
700	Epidemiology and Treatment of Systemic Sclerosis in Korea. <i>Journal of Rheumatic Diseases</i> , 2022, 29, 200-214.	0.4	5
701	Incidence, prevalence and regional distribution of systemic sclerosis and related interstitial lung Disease: A nationwide retrospective cohort study. <i>Chronic Respiratory Disease</i> , 2022, 19, 147997312211255.	1.0	6
702	Immunomodulatory treatment of interstitial lung disease. <i>Therapeutic Advances in Respiratory Disease</i> , 2022, 16, 175346662211170.	1.0	15
703	Question 112. , 2022, , 245-246.		0
704	Impact of Reduction in Antifibrotic Treatment on Mortality in Idiopathic Pulmonary Fibrosis. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
705	Coexistence of anti-topoisomerase I and anticentromere antibodies in a patient with systemic sclerosis. Efficacy of treatment combining rituximab and nintedanib. A case report. <i>International Journal of Immunopathology and Pharmacology</i> , 2022, 36, 039463202211153.	1.0	0
706	Multiple Choice Questions with explanations. , 2022, , 1-267.		0
707	Nintedanib in children and adolescents with fibrosing interstitial lung diseases. <i>European Respiratory Journal</i> , 2023, 61, 2201512.	3.1	31
708	Clinical Predictors of Lung-Function Decline in Systemic-Sclerosis-Associated Interstitial Lung Disease Patients with Normal Spirometry. <i>Biomedicines</i> , 2022, 10, 2129.	1.4	5
709	Perspective Chapter: Pulmonary System and Sjogrenâ€™s Syndrome. , 0, , .		0
710	Systemic sclerosis associated interstitial lung disease: a conceptual framework for subclinical, clinical and progressive disease. <i>Rheumatology</i> , 2023, 62, 1877-1886.	0.9	2

#	ARTICLE	IF	CITATIONS
711	Dersimelagon, a novel oral melanocortin 1 receptor agonist, demonstrates disease-modifying effects in preclinical models of systemic sclerosis. <i>Arthritis Research and Therapy</i> , 2022, 24, .	1.6	9
712	Diagnosing interstitial lung disease by multidisciplinary discussion: A review. <i>Frontiers in Medicine</i> , 0, 9, .	1.2	4
713	Systemic Sclerosis Association with Malignancy. <i>Clinical Reviews in Allergy and Immunology</i> , 2022, 63, 398-416.	2.9	7
714	Longitudinal study of patients with antimelanoma differentiation-associated gene 5 antibody-positive dermatomyositis-associated interstitial lung disease. <i>Rheumatology</i> , 0, , .	0.9	3
716	Extent of fibrosis and lung function decline in patients with systemic sclerosis and interstitial lung disease: data from the SENSICIS trial. <i>Rheumatology</i> , 2023, 62, 1870-1876.	0.9	12
717	Plasticity towards Rigidity: A Macrophage Conundrum in Pulmonary Fibrosis. <i>International Journal of Molecular Sciences</i> , 2022, 23, 11443.	1.8	10
718	Multidisciplinary teams in the clinical care of fibrotic interstitial lung disease: current perspectives. <i>European Respiratory Review</i> , 2022, 31, 220003.	3.0	11
719	The Role of Myofibroblasts in Physiological and Pathological Tissue Repair. <i>Cold Spring Harbor Perspectives in Biology</i> , 2023, 15, a041231.	2.3	31
720	The Effect of Nintedanib in Post-COVID-19 Lung Fibrosis: An Observational Study. <i>Critical Care Research and Practice</i> , 2022, 2022, 1-7.	0.4	6
723	Therapeutic effects of adipose-derived mesenchymal stem/stromal cells with enhanced migration ability and hepatocyte growth factor secretion by low-molecular-weight heparin treatment in bleomycin-induced mouse models of systemic sclerosis. <i>Arthritis Research and Therapy</i> , 2022, 24, .	1.6	6
724	Factors associated with interstitial lung disease and the progressive fibrosing phenotype in rheumatoid arthritis-related interstitial lung disease. <i>Medical Journal Armed Forces India</i> , 2022, , .	0.3	2
725	VII. Clinical Approach for Interstitial Lung Disease in Connective Tissue Diseases-including Molecular Targeted Therapy-. <i>The Journal of the Japanese Society of Internal Medicine</i> , 2021, 110, 2206-2212.	0.0	0
726	Impact of reduction in antifibrotic treatment on mortality in idiopathic pulmonary fibrosis. <i>Respiratory Medicine</i> , 2022, 204, 107015.	1.3	2
727	Guidelines of the Polish Respiratory Society on the Diagnosis and Treatment of Progressive Fibrosing Interstitial Lung Diseases Other than Idiopathic Pulmonary Fibrosis. <i>Advances in Respiratory Medicine</i> , 2022, 90, 425-450.	0.5	4
728	A genome-wide association study identifying single nucleotide polymorphisms in the <i>PPFIBP2</i> gene was predictive for interstitial lung disease in rheumatoid arthritis patients. <i>Rheumatology Advances in Practice</i> , 2022, 6, .	0.3	2
730	Sarcoidosis: Updates on therapeutic drug trials and novel treatment approaches. <i>Frontiers in Medicine</i> , 0, 9, .	1.2	10
731	Therapeutic Effects of Omentin-1 on Pulmonary Fibrosis by Attenuating Fibroblast Activation via AMP-Activated Protein Kinase Pathway. <i>Biomedicines</i> , 2022, 10, 2715.	1.4	2
732	Cohort Enrichment Strategies for Progressive Interstitial Lung Disease in Systemic Sclerosis From European Scleroderma Trials and Research. <i>Chest</i> , 2023, 163, 586-598.	0.4	5

#	ARTICLE	IF	CITATIONS
733	Systemic sclerosis-associated interstitial lung disease in the EUSTAR database: analysis by region. <i>Rheumatology</i> , 2023, 62, 2178-2188.	0.9	7
734	Rituximab for the treatment of connective tissue disease-associated interstitial lung disease: A systematic review and meta-analysis. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	3
735	Diagnosis of pleuroparenchymal fibroelastosis: A review. <i>Monaldi Archives for Chest Disease</i> , 0, , .	0.3	0
736	Interstitial Pneumonia with Autoimmune Features: Implications for Clinical Practice. <i>Current Pulmonology Reports</i> , 0, , .	0.5	0
738	Effectiveness and safety of tocilizumab in patients with systemic sclerosis: a propensity score matched controlled observational study of the EUSTAR cohort. <i>RMD Open</i> , 2022, 8, e002477.	1.8	7
739	Progression of Pulmonary Fibrosis According to Radiological Pattern in Asbestosis. <i>Annals of the American Thoracic Society</i> , 0, , .	1.5	0
741	Ameliorating Fibrosis in Murine and Human Tissues with END55, an Endostatin-Derived Fusion Protein Made in Plants. <i>Biomedicines</i> , 2022, 10, 2861.	1.4	2
742	Management of Interstitial Lung Diseases: A Consensus Statement of the Indian Chest Society and National College of Chest Physicians (India). <i>The Indian Journal of Chest Diseases &amp; Allied Sciences</i> , 2022, 62, 73-98.	0.1	0
743	Clinical, imaging, and blood biomarkers to assess 1-year progression risk in fibrotic interstitial lung diseasesâDevelopment and validation of the honeycombing, traction bronchiectasis, and monocyte (HTM)-score. <i>Frontiers in Medicine</i> , 0, 9, .	1.2	2
744	Pulmonary Fibrosis: A Common Cause with Rheumatologists and Physicians. <i>The Indian Journal of Chest Diseases &amp; Allied Sciences</i> , 2022, 62, 113-115.	0.1	0
745	Rituximab versus intravenous cyclophosphamide in patients with connective tissue disease-associated interstitial lung disease in the UK (RECITAL): a double-blind, double-dummy, randomised, controlled, phase 2b trial. <i>Lancet Respiratory Medicine</i> ,the, 2023, 11, 45-54.	5.2	73
746	Rituximab for connective tissue disease-associated interstitial lung disease. <i>Lancet Respiratory Medicine</i> ,the, 2023, 11, 3-4.	5.2	0
747	Risk factors for lung function decline in systemic sclerosis-associated interstitial lung disease in a large single-centre cohort. <i>Rheumatology</i> , 2023, 62, 2501-2509.	0.9	7
748	Machine learning in radiology: the new frontier in interstitial lung diseases. <i>The Lancet Digital Health</i> , 2023, 5, e41-e50.	5.9	18
749	Revealing stromal and lymphoid sources of <i>Col3a1</i> -expression during inflammation using a novel reporter mouse. , 2022, 1, .		0
750	Advances in the Treatment of Systemic Sclerosis. , 2022, 1, 61.		0
751	Systemic sclerosis. <i>Lancet</i> , The, 2023, 401, 304-318.	6.3	73
752	Autologous hematopoietic stem cell transplantation improves long-term survivalâdata from a national registry. <i>Arthritis Research and Therapy</i> , 2022, 24, .	1.6	1

#	ARTICLE	IF	CITATIONS
753	Pathological Roles of Pulmonary Cells in Acute Lung Injury: Lessons from Clinical Practice. <i>International Journal of Molecular Sciences</i> , 2022, 23, 15027.	1.8	2
754	<scp>Clinâ€STAR</scp> corner: Recent <scp>practiceâ€changing</scp> studies at the interface of pulmonary and critical care medicine and geriatrics. <i>Journal of the American Geriatrics Society</i> , 2023, 71, 705-710.	1.3	0
755	Nintedanib for non-IPF progressive pulmonary fibrosis: 12-month outcome data from a real-world multicentre observational study. <i>ERJ Open Research</i> , 2023, 9, 00423-2022.	1.1	5
756	Phenotypic screening of 1,953 FDA-approved drugs reveals 26 hits with potential for repurposing for Peyronieâ€™s disease. <i>PLoS ONE</i> , 2022, 17, e0277646.	1.1	3
757	The Microbiome in Systemic Sclerosis: Pathophysiology and Therapeutic Potential. <i>International Journal of Molecular Sciences</i> , 2022, 23, 16154.	1.8	2
759	Interstitial lung disease in rheumatoid arthritis: A multidisciplinary problem in rheumatology and pulmonology. <i>Nauchno-Prakticheskaya Revmatologiya</i> , 2022, 60, 517-534.	0.2	5
760	Analysis of Clinical Characteristics of Connective Tissue Disease-Associated Interstitial Lung Disease in 161 Patients: A Retrospective Study. <i>International Journal of General Medicine</i> , 0, Volume 15, 8617-8625.	0.8	3
761	Structured report improves radiology residentsâ€™ performance in reporting chest high-resolution computed tomography: a study in patients with connective tissue disease. , 2022, 28, 569-575.		1
763	Progressive pulmonary fibrosis: an expert group consensus statement. <i>European Respiratory Journal</i> , 2023, 61, 2103187.	3.1	25
764	Beneficial effects of nintedanib on cardiomyopathy in patients with systemic sclerosis: a pilot study. <i>Rheumatology</i> , 2023, 62, 2550-2555.	0.9	4
765	Epiregulin is a dendritic cellâ€derived EGFR ligand that maintains skin and lung fibrosis. <i>Science Immunology</i> , 2022, 7, .	5.6	8
767	Clinical Images: Severe interstitial lung disease in SjÃ¶gren disease â€” What happens in the lungs? Inflammation or fibrosis?. <i>ACR Open Rheumatology</i> , 2023, 5, 61-62.	0.9	2
769	Current best clinical practices for monitoring of interstitial lung disease. <i>Expert Review of Respiratory Medicine</i> , 2022, 16, 1153-1166.	1.0	1
770	Hypersensitivity pneumonitis: An infrequent cause of chronic lung fibrosis in Africa?. <i>African Journal of Thoracic and Critical Care Medicine</i> , 0, , 144.	0.3	1
771	Nintedanib in Asian patients with progressive fibrosing interstitial lung diseases: Results from the <scp>INBUILD</scp> trial. <i>Respirology</i> , 2023, 28, 465-474.	1.3	2
772	Dysregulated B cell function and disease pathogenesis in systemic sclerosis. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	6
773	ERS International Congress 2022: highlights from the Interstitial Lung Diseases Assembly. <i>ERJ Open Research</i> , 2023, 9, 00584-2022.	1.1	1
774	Expert consensus on the management of systemic sclerosis-associated interstitial lung disease. <i>Respiratory Research</i> , 2023, 24, .	1.4	40

#	ARTICLE	IF	CITATIONS
775	Diagnosing lung involvement in inflammatory rheumatic diseasesâ€”Where do we currently stand?. <i>Frontiers in Medicine</i> , 0, 9, .	1.2	2
776	Nintedanib in an elderly non-small-cell lung cancer patient with severe steroid-refractory checkpoint inhibitor-related pneumonitis: A case report and literature review. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	3
777	Pulmonary Fibrosis and Progressive Pulmonary Fibrosis in a Prospective Registry of Interstitial Lung Diseases in Eastern Siberia. <i>Life</i> , 2023, 13, 212.	1.1	1
778	Cyclophosphamide Pulse Therapy in the Treatment of Systemic Sclerosis Associated Interstitial Lung Disease: An Observational Study. <i>The Indian Journal of Chest Diseases &amp; Allied Sciences</i> , 2023, 64, 263-268.	0.1	0
779	Real-world impact of antifibrotics on prognosis in patients with progressive fibrosing interstitial lung disease. <i>RMD Open</i> , 2023, 9, e002667.	1.8	3
780	Lung function trajectory of rheumatoid arthritisâ€”associated interstitial lung disease. <i>Rheumatology</i> , 2023, 62, 3014-3024.	0.9	5
781	Understanding Interstitial Lung Diseases Associated with Connective Tissue Disease (CTD-ILD): Genetics, Cellular Pathophysiology, and Biologic Drivers. <i>International Journal of Molecular Sciences</i> , 2023, 24, 2405.	1.8	5
782	Responses to exercise in systemicâ€”sclerosisâ€”associated interstitial lung disease. <i>Clinical Physiology and Functional Imaging</i> , 2023, 43, 253-262.	0.5	0
783	Real-world utility of a genomic classifier in establishing a diagnosis of newly identified interstitial lung disease. <i>Respiratory Medicine and Research</i> , 2023, 83, 100996.	0.4	0
784	Characterising the autoantibody repertoire in systemic sclerosis following myeloablative haematopoietic stem cell transplantation. <i>Annals of the Rheumatic Diseases</i> , 2023, 82, 670-680.	0.5	4
785	New Frontiers in Therapeutics for Interstitial Lung Diseases. <i>American Journal of Respiratory and Critical Care Medicine</i> , 0, , .	2.5	0
786	3. Recent Progress in Management of Interstitial Lung Disease Associated with Connective Tissue Diseases. <i>The Journal of the Japanese Society of Internal Medicine</i> , 2022, 111, 90a-96a.	0.0	0
787	Sclerodermaâ€”Systemic Sclerosis. , 2023, , 712-722.		0
788	Interstitial Pneumonia with Autoimmune Features. , 2023, , 241-250.		0
789	Treatment of interstitial lung disease in systemic sclerosis. <i>Medic Ro</i> , 2023, 1, 21.	0.0	0
791	Clinical and immunological variants of ANCA-associated systemic vasculitis: a look at the pulmonary fibrosis in microscopic polyangiitis with anti-myeloperoxidase antibodies and rheumatoid factor. Literature review and own observation. <i>Nauchno-Prakticheskaya Revmatologiya</i> , 2023, 61, 62-69.	0.2	0
792	Role of rituximab in the treatment of systemic sclerosis: A literature review. <i>Modern Rheumatology</i> , 2023, 33, 1068-1077.	0.9	3
793	Pulmonary 5-HT2B receptor expression in fibrotic interstitial lung diseases. <i>Acta Histochemica</i> , 2023, 125, 152024.	0.9	0

#	ARTICLE	IF	CITATIONS
794	Nintedanib prevents TGF- $\beta$ 2-induced epithelial-mesenchymal transition in retinal pigment epithelial cells. <i>Biomedicine and Pharmacotherapy</i> , 2023, 161, 114543.	2.5	6
795	Scleroderma Skin. <i>Rheumatic Disease Clinics of North America</i> , 2023, 49, 249-262.	0.8	0
796	Interstitial Lung Disease. <i>Rheumatic Disease Clinics of North America</i> , 2023, 49, 279-293.	0.8	3
797	Connective Tissue Disease Associated Interstitial Lung Disease. <i>Immunology and Allergy Clinics of North America</i> , 2023, 43, 229-244.	0.7	1
798	Serum and bronchoalveolar lavage fluid levels of soluble B7H3 in patients with interstitial lung diseases. <i>Respiratory Medicine</i> , 2023, 212, 107224.	1.3	1
799	Effects of Ruxolitinib on fibrosis in preclinical models of systemic sclerosis. <i>International Immunopharmacology</i> , 2023, 116, 109723.	1.7	5
800	Study protocol of an international patient-led registry in patients with pulmonary fibrosis using online home monitoring: I-FILE. <i>BMC Pulmonary Medicine</i> , 2023, 23, .	0.8	3
801	The Molecular Mechanisms of Systemic Sclerosis-Associated Lung Fibrosis. <i>International Journal of Molecular Sciences</i> , 2023, 24, 2963.	1.8	8
802	Diagnosis and Management of Myositis-Associated Lung Disease. <i>Chest</i> , 2023, 163, 1476-1491.	0.4	10
803	The Lung Transplant Candidate, Indications, Timing, and Selection Criteria. <i>Clinics in Chest Medicine</i> , 2023, 44, 15-33.	0.8	0
804	Serum Immunoglobulin G (IgG) Subclasses in a Cohort of Systemic Sclerosis Patients. <i>Journal of Personalized Medicine</i> , 2023, 13, 309.	1.1	0
806	Identification and management of connective tissue disease-associated interstitial lung disease: evidence-based Japanese consensus statements. <i>Expert Review of Respiratory Medicine</i> , 2023, 17, 71-80.	1.0	0
807	Nintedanib in Idiopathic Pulmonary Fibrosis: Tolerability and Safety in a Real Life Experience in a Single Centre in Patients also Treated with Oral Anticoagulant Therapy. <i>Pharmaceuticals</i> , 2023, 16, 307.	1.7	7
808	Effect of nintedanib in patients with systemic sclerosis-associated interstitial lung disease and risk factors for rapid progression. <i>RMD Open</i> , 2023, 9, e002859.	1.8	7
809	Diffuse myocardial fibrosis precedes subclinical functional myocardial impairment and provides prognostic information in systemic sclerosis. <i>European Heart Journal Cardiovascular Imaging</i> , 2023, 24, 373-382.	0.5	3
810	Diagnosis and Pharmacologic Management of Fibrotic Interstitial Lung Disease. <i>Life</i> , 2023, 13, 599.	1.1	2
811	Real-life efficacy and safety of nintedanib in systemic sclerosis-interstitial lung disease: data from an Italian multicentre study. <i>RMD Open</i> , 2023, 9, e002850.	1.8	9
812	Characteristics and risk factors of mortality in patients with systemic sclerosis-associated interstitial lung disease. <i>Annals of Medicine</i> , 2023, 55, 663-671.	1.5	4



#	ARTICLE	IF	CITATIONS
813	Development and validation of a Systemic Sclerosis Health Literacy Scale. <i>Frontiers in Public Health</i> , 0, 11, .	1.3	1
814	State-of-the-art evidence in the treatment of systemic sclerosis. <i>Nature Reviews Rheumatology</i> , 2023, 19, 212-226.	3.5	21
815	Interstitial pneumonia with autoimmune features and histologic usual interstitial pneumonia treated with anti-fibrotic versus immunosuppressive therapy. <i>Respiratory Investigation</i> , 2023, 61, 297-305.	0.9	5
816	The diagnostic trajectories of Danish patients with autoimmune rheumatologic disease associated interstitial lung disease: an interview-based study. <i>European Clinical Respiratory Journal</i> , 2023, 10, .	0.7	1
817	Clinical Trial Enrichment in Systemic Sclerosis-Associated Interstitial Lung Disease. <i>Chest</i> , 2023, 163, 475-476.	0.4	0
818	Randomized Phase 2 Placebo-Controlled Trial of Nintedanib for the Treatment of Radiation Pneumonitis. <i>International Journal of Radiation Oncology Biology Physics</i> , 2023, 116, 1091-1099.	0.4	5
819	A Composite Serum Biomarker Index for the Diagnosis of Systemic Sclerosis-Associated Interstitial Lung Disease: A Multicenter, Observational Cohort Study. <i>Arthritis and Rheumatology</i> , 2023, 75, 1424-1433.	2.9	9
820	Advances in Clinical Research of Interstitial Lung Disease with Autoimmune Characteristics. <i>Advances in Clinical Medicine</i> , 2023, 13, 3752-3758.	0.0	0
821	Autoantibodies against PIP4K2B and AKT3 Are Associated with Skin and Lung Fibrosis in Patients with Systemic Sclerosis. <i>International Journal of Molecular Sciences</i> , 2023, 24, 5629.	1.8	3
822	Bacterial Infections Associated with Immunosuppressive Agents Commonly Used in Patients with Interstitial Lung Diseases. <i>Pathogens</i> , 2023, 12, 464.	1.2	1
823	Interstitial lung disease associated with inflammatory myositis: Autoantibodies, clinical phenotypes, and progressive fibrosis. <i>Frontiers in Medicine</i> , 0, 10, .	1.2	3
824	Cutaneous Manifestations of Scleroderma. <i>Journal of the Dermatology Nurses' Association</i> , 2023, 15, 86-96.	0.1	0
825	Functional roles of <scp>CD26</scp>/<scp>DPP4</scp> in bleomycinâ€induced pulmonary fibrosis. <i>Physiological Reports</i> , 2023, 11, .	0.7	3
826	Efficacy and Safety of Nintedanib in Patients with Connective Tissue Disease-Interstitial Lung Disease (CTD-ILD): A Real-World Single Center Experience. <i>Diagnostics</i> , 2023, 13, 1221.	1.3	1
827	Recent advances in the treatment of systemic sclerosis associated interstitial lung disease. <i>Frontiers in Medicine</i> , 0, 10, .	1.2	1
828	Weight loss and outcomes in subjects with progressive pulmonary fibrosis: data from the INBUILD trial. <i>Respiratory Research</i> , 2023, 24, .	1.4	1
829	Nationwide epidemiologic study for fibrosing interstitial lung disease (F-ILD) in South Korea: a population-based study. <i>BMC Pulmonary Medicine</i> , 2023, 23, .	0.8	1
830	Imaging Fibrosis. <i>PET Clinics</i> , , .	1.5	0

#	ARTICLE	IF	CITATIONS
831	Anti-U11/U12 Antibodies as a Rare but Important Biomarker in Patients with Systemic Sclerosis: A Narrative Review. <i>Diagnostics</i> , 2023, 13, 1257.	1.3	2
833	Use of a pulmosphere model to evaluate drug antifibrotic responses in interstitial lung diseases. <i>Respiratory Research</i> , 2023, 24, .	1.4	3
835	Systemic Sclerosis (Scleroderma) and Raynaudâ€™s Phenomenon. , 2023, , 111-132.		0
836	Progressive pulmonary fibrosis in systemic autoimmune diseases. A real life study. <i>ReumatologÃa ClÃnica (English Edition)</i> , 2023, 19, 211-214.	0.2	1
837	Clinical Trials in Systemic Sclerosis: Crossroads and Opportunities. <i>Arthritis and Rheumatology</i> , 0, , .	2.9	0
838	Immune-mediated lung diseases: A narrative review. <i>Frontiers in Medicine</i> , 0, 10, .	1.2	3
839	Pharmacological management of systemic sclerosis associated interstitial lung disease. <i>Expert Opinion on Pharmacotherapy</i> , 0, , 1-10.	0.9	0
840	Unclassifiable Interstitial Lung Disease. , 2023, , 671-682.		0
841	Idiopathic Pulmonary Fibrosis and the Many Faces of UIP. , 2023, , 549-560.		0
842	Systemic Sclerosis and the Lung. , 2023, , 193-205.		0
843	Description of a single centre cohort of patients with systemic sclerosis from the University Hospital of Buenos Aires and factors associated with lung function deterioration. A retrospective study. <i>ReumatologÃa ClÃnica</i> , 2023, 19, 351-357.	0.2	2
844	Development and validation of algorithms to build an electronic health record based cohort of patients with systemic sclerosis. <i>PLoS ONE</i> , 2023, 18, e0283775.	1.1	1
846	Can transbronchial lung cryobiopsy benefit adaptive treatment strategies in connective tissue disease-associated interstitial lung disease?. <i>BMC Pulmonary Medicine</i> , 2023, 23, .	0.8	0
847	Management of interstitial lung disease in patients with autoimmune disease-related interstitial lung disease. <i>Multidisciplinary Respiratory Medicine</i> , 0, 18, .	0.6	2
848	Prognostic value of automated assessment of interstitial lung disease on CT in systemic sclerosis. <i>Rheumatology</i> , 2024, 63, 103-110.	0.9	4
849	Prognostic biomarkers of progressive pulmonary fibrosis in patients with interstitial lung diseases. <i>Meditsinskiy Sovet</i> , 2023, , 86-91.	0.1	0
864	Interstitial lung diseases: an overview. , 2023, , 23-39.		0
865	Systemic inflammatory diseases with lung involvement. , 2023, , 237-253.		0

#	ARTICLE	IF	CITATIONS
866	Chronic Respiratory Disease: COPD, IPF. Practical Issues in Geriatrics, 2023, , 311-330.	0.3	0
877	Cryobiopsy in Interstitial Lung Disease: Is It Prime Time?. Current Pulmonology Reports, 0, , .	0.5	0
898	Pulmonary Disease. , 2023, , 1-26.		0
914	Treatable Traits in Systemic Sclerosis. Clinical Reviews in Allergy and Immunology, 2023, 65, 251-276.	2.9	3
916	Back to the future: targeting the extracellular matrix to treat systemic sclerosis. Nature Reviews Rheumatology, 2023, 19, 713-723.	3.5	2
957	Systemic sclerosis interstitial lung disease: unmet needs and potential solutions. Nature Reviews Rheumatology, 0, , .	3.5	0
972	Recent Advances in Treatment of Systemic Sclerosis and Morphea. American Journal of Clinical Dermatology, 2024, 25, 213-226.	3.3	0
1007	Pulmonary Disease. , 2024, , 571-596.		0